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Children of Down syndrome (DS), the most common congenital disease, are at high 
risk of developing a specific subtype of acute myeloid leukemia, acute 
megakaryoblastic leukemia (AMKL). According to Malaysia-Singapore multicenter 
leukemia studies for childhood acute leukemia, the prevalence of AMKL in Singapore 
and Malaysia is strikingly high as compared to those in the worldwide populations, and 
its prognosis is unfavorable. Despite such widespread and local relevance, the 
mechanistic basis for AMKL remains elusive. 
To discover currently unknown genetic alterations associated with AMKL, an 
AMKL mouse model was developed employing retroviral insertional mutagenesis 
(RIM) on the genetically engineered mouse with alterations in Gata-1 and Runx1 genes, 
both of which are well documented to be critical for normal megakaryopoiesis and 
deregulated in AMKL. As RIM enables easy identification of affected genes potentially 
involved in leukemogenesis, I readily identified potential AMKL genes, which are 
classified into two signaling pathways, namely JAK-STAT and Notch pathways. 
In order to validate whether the genetic alterations detected in the RIM mouse 
model are also affected in human AMKL samples, I employed targeted deep 
sequencing strategy in 40 AMKL patient samples and 7 AMKL cell lines. Besides 
known AMKL-related genetic changes such as GATA-1 point mutation and trisomy 21 
causing an extra copy of RUNX1, genetic mutations in Notch and JAK-STAT pathways 
were frequently identified. Subsequent experimental characterization of mutants and 
known functions of mutated domains suggest that these mutations lead to the activation 
of JAK-STAT pathway and inactivation of Notch pathway. 
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To further validate the oncogenic role of Notch and JAK-STAT pathways in 
AMKL, the inhibitory effect on AMKL cell lines by Notch agonist, phenetyl 
isothiocyanate (PEITC), and JAK inhibitor 1 were examined. Both drugs significantly 
suppressed leukemia cell proliferation by inducing apoptosis individually as a single 
agent and synergistically as a combination therapy. This potent inhibition holds a 
potential of therapeutic application of Notch agonist alone or in combination with JAK-
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Megakaryopoiesis is the process concerned with the unique maturation of 
megakaryocytes (MKs) that is derived from the pluripotent hematopoietic stem cells 
(HSCs) and involves multipotential stem/progenitor cells commitment1, nuclear 
polyploidization, development of an extensive internal demarcation membrane system, 
formation of proplatelet processes and finally the controlled release of functional 
platelets into the vascular sinusoids within the bone marrow which is critical for normal 
hemostasis2 (Figure 1.1). The hallmark of the MK is its large diameter (50-100 μm) and 
its single, multilobulated, polyploid nucleus, accounting for less than 1% of marrow 
elements3. A mature MK can produce up to 104 platelets during its lifespan4. The adult 
human produces 1011 platelets daily at steady state by the cytoplasmic fragmentation of 
MKs and the production level can increase 10- to 20-fold in response to heightened 
demand and an additional 5- to 10-fold under the stimulation of thrombopoietin (TPO)-
mimetic drugs5-7. A supportive bone marrow stroma consisting of osteoblasts, 
endothelial and other cells, matrix glycosaminoglycans, cytokine signaling [TPO, 
interleukin-6 (IL-6), interferon-gamma (IFN-γ), stem cell factor (SCF) and stromal cell-
derived factor-1 (SDF-1)] and multiple transcription factors (Runx1, Gata-1, Fli1 and c-







     
Figure 1.1: Megakaryopoiesis. 
Schematic diagram illustrates the process of megakaryopoiesis and platelet production 
which derived from HSC through successive lineage commitment steps, including 
proliferation and differentiation of MK progenitors and maturation of MKs into large 
polyploidy mature MKs that shed platelets. Abbreviations: MK, megakaryocyte; BFU-
MK, burst forming units-megakaryocyte; CFU-MK, colony forming units-




1.1.1 Megakaryopoiesis during development in mammals 
 
Hematopoiesis, which refers to the development and production of the diverse types of 
blood cells in the organism, occurs in sequential stages that involve 2 distinct waves, 
namely primitive and definitive hematopoiesis (Figure 1.2). The multiple waves of 
blood cell development have been best studied in mouse, which has ultimately served as 
the main mammalian model system, integral to our understanding of hematopoietic 
biology.  
Primitive hematopoiesis first emerges in mammals within the blood islands of 
the extraembryonic yolk sac (YS) at embryonic day 7.5 (E7.5) and is defined by a 
relatively rapid commitment of the hemangioblast mesodermal precursor to 
hematopoietic precursors and endothelial cells10-11. Majority of the hemangioblast 
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precursors also contains megakaryocytic potential, indicating that megakaryocytic 
lineage is also an integral component of embryonic hematopoiesis12. The unique 
bipotential primitive megakaryocyte/ erythroid progenitors (MEPs) transiently appear in 
the murine YS between embryonic days 7.25 and 9.0 (E7.25-E9.0) along with 
unipotential primitive erythroid and MK progenitors12. 
The second wave of definitive hematopoiesis is multilineage that results in the 
production of all lineages of blood cells that populate the organism and is characterized 
by the emergence of multipotent HSCs13. Definitive MEPs arise and expand in the YS 
with MK progenitors and definitive erythroid progenitors (burst-forming units-erythroid 
[BFU-Es]), accompanied temporally by mast cells, granulocyte, macrophage, and 
multipotential high proliferative potential colony forming cells between embryonic days 
8.25 and 10.0 (E8.25-E10.0) prior to the formation of fetal liver14-17. The presence of 
megakaryocytic cells based on the expression of glycoprotein-1bβ (GP1bβ)-positive 
cells in the mouse conceptus is first detected exclusively in the yolk sac at embryonic 
day 9.5 (E9.5)12. No GP1bβ-positive cells are evident in the embryo proper but the 
GP1bβ-positive cells are found to be abundant in the surrounding maternal decidual 
tissues12. Subsequently, the number of MK progenitors begins to decline in the YS and 
expand in the fetal liver at embryonic day 10.5 (E10.5), which likely reflects a 
contribution of MK progenitors from aorta-gonad-mesonephros (AGM)-derived HSCs 
that are evident in the liver beginning of embryonic day 11 (E11)12. 
The rapid initiation of platelet production in a process termed thrombopoiesis, is 
evident by the presence of large and highly reticulated platelets detected in the 
embryonic vasculature between embryonic day 10.5 to 11.5 (E10.5-E11.5) and these 
reticulated circulating platelets continued to persist in elevated levels through to 
embryonic day 15.5 (E15.5) which suggests that active thrombopoiesis is required in 
 4 
 
the developing fetus12. Fetal platelets are anucleate, discoid and biconvex in shape, 
which is similar to adult platelets12. However, fetal platelets are distinguished by large 
size with a diameter 1.6 fold larger than adult platelets, and other notable features such 
as massive canalicular system and the presence of small alpha granules12. The average 
platelet diameter as well as the levels of reticulated platelets decreased during ontogeny 













Figure 1.2: Hematopoietic development in human and mouse. 
Schematic diagram illustrates the timeline and shifting sites of hematopoietic events 
during embryonic development in the human and mouse. Arrows above indicate the 
onset of specific hematopoietic cell generation and/or appearance; arrows below 
indicate the earliest time of colonization of the secondary hematopoietic territories. 
Abbreviations: HSC, hematopoietic stem cell; AGM, aorta-gonad-mesonephros; dpc, 








1.1.1.1 Characteristics of neonatal and adult megakaryopoiesis   
 
The molecular differences between fetal/neonatal and adult megakaryopoiesis (Table 
1.1), play a critical role in the pathogenesis of several megakaryocytic disorders with 
developmental stage-specific features. Several studies have demonstrated that fetal and 
neonatal MK progenitors have a higher proliferation rate and significantly larger MK 
colonies generated in colony assays than adult progenitors21-23. Production of MKs by 
fetal and neonatal MK progenitors are significantly smaller, more cytoplasmically 
mature, and of lower ploidy than adult MKs24-25. Significantly higher concentration of 
TPO is also observed in healthy neonates compared to normal adults22,26,27. In addition, 
the response to TPO concentrations is more sensitive in healthy neonates than in normal 
adults22,26,27. 
 















1.1.2 Megakaryocytic lineage specification in adult  
 
The hematopoietic system is organized and schematically portrayed as the “tree of 
hematopoiesis”, which depicts the process of hierarchical hematopoiesis conveying the 
possible developmental choices and is generally conserved throughout vertebrae 
evolution29 (Figure 1.3). Hematopoiesis in adult vertebrates is a dynamic process that 
requires constant replenishment of terminally differentiated hematopoietic cells 
(leukocytes, erythrocytes and platelets) which have a limited life span. Therefore, 
homeostasis of the hematopoietic system is considered to occur by the recruitment of 
HSCs, which are a rare population of multipotent (the potential to give rise to all blood 
cell lineages) cells in the bone marrow. The capacity of HSCs to undergo extensive 
self-renewal (the ability to generate identical daughter cells with the same unrestricted 
proliferation potential) and commitment to differentiation to sustain mature blood cell 
production is crucial for the maintenance of life-long multilineage hematopoiesis 
(Figure 1.3).  
 Multilineage hematopoiesis can be reconstituted following transplantation of a 
single HSC31. The HSC compartment is composed of long-term (LT)-HSCs, which can 
reconstitute the hematopoietic system for life and prevent premature HSC pool 
exhaustion by remaining quiescent under steady state, whereas short-term (ST)-HSCs 
can sustain hematopoiesis temporarily either by limited self-renewal activity or  
undergo differentiation into committed progenitors cells to repopulate myeloid or 
lymphoid cells. Differences between LT-HSCs and ST-HSCs have been characterized 
as having differences in marrow homing32.  
Multi-potent progenitor (MPP), which is defined as a cell population that has 
lost the self-renewal capacity of HSC, gives rise to committed oligopotent progenitors, 
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namely common myeloid progenitor (CMP) and common lymphoid progenitor (CLP)33. 
These highly proliferative CMPs and CLPs generate a variety of lineage-restricted 
precursors and progressively acquire characteristics of their respective terminally 
differentiated mature blood cells.  
During the course of hematopoiesis, the highly regulated differentiation of 
quiescent HSC along one lineage involves lineage commitment, which is defined as the 
initiation of developmental program(s) that lead to a particular cell fate, and is 
accompanied by the gradual lost of the capacity for multi-lineage differentiation 
(lineage maintenance)34. Lineage commitment and maintenance are complementary 
processes that guide cell fate decisions. Thus, cells committed to a particular lineage 










Figure 1.3: Hematopoiesis differentiation chart in adult mammals. 
Flow chart illustrates the “classical” model of hematopoiesis, showing a hierarchy with 
HSCs differentiation into different progenitors. The maturation patterns of myeloid and 
lymphoid cells into their respective lineages are also shown. Abbreviations: HSC, 
hematopoietic stem cell; LT-HSC, long-term HSC; ST-HSC, short-term HSC; MPP, 
multipotent progenitor; CMP, common myeloid progenitor; GMP, 
granulocyte/monocyte progenitor; MEP, megakaryocyte/erythrocyte progenitor; CLP, 
common lymphoid progenitor; MK, megakaryocyte; Pro-E, pro-erythroblast; B, B-cell; 
T, T-cell; DN, double negative T-cell precursors; DP, double positive T-cell precursors. 




According to the “classical” model of hematopoiesis, CMP and CLP are 
symmetrically derived from the same MPP, representing the first step of irreversible 
lineage commitment from HSCs during early hematopoietic ontogeny36. 
 The CMPs give rise to the megakaryocyte/erythroid progenitors (MEPs) 
committed to the differentiation and formation of erythrocytes and 
megakaryocytes/platelets and also granulocyte/macrophage progenitors (GMPs) which 
are able to differentiate into granulocytes including neutrophils, eosinophils and 
basophils, as well as monocytes which further differentiate into macrophages. The 
myeloid lineage is involved in various functions such as innate immunity, adaptive 
immunity (WBCs), blood clotting (platelets) and oxygen transportation throughout the 
organism (erythrocytes). 
 The CLP carries differentiation potential for all types of lymphoid cells 
including B cells, T cells and natural killer (NK) cells, through their respective 
precursors. Immediately following the CLP stage, development of B cells and T cells 
occurs separately, with B cells developing in the bone marrow and T cells in the 
thymus.  In the bone marrow, earliest B lineage precursors, pro-B cells develop through 
pre-B cells into immature B cells which translocate into the peripheral lymphoid organs 
to mature through transitional stages into mature B cells. In the thymus, early thymic 
progenitors develops through CD4 CD8  double-negative (DN) and CD4+CD8+ double-
positive (DP) stages into mature T cells. B and T lymphocytes are responsible primarily 
for the basic functions of antibody production by terminally differentiated plasma cells 
and cell-mediated immune responses including T helper, T regulatory, and cytotoxic T 
lymphocyte effector cell functions, respectively.                                                                                                              
 MK lineage arises from MEP through differentiation of CMP derived from 
HSCs. In response to environmental factors, cytokines and chemokines, bipotential 
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MEP can develop into the highly proliferative, most primitive MK progenitor that is the 
burst-forming unit-MK (BFU-MK), or the more mature smaller progenitor designated 
colony-forming unit-MK (CFU-MK)37-38. BFU-MK can develop into large, complex 
and multifocal colonies that include satellite collections of MKs and contain up to 40 to 
500 MKs within 1 week, whereas CFU-MK develop into a small, simple and unifocal 
colony containing from 3 to 50 mature MKs that vary in their proliferation potential39 
(Figure 1.4). The transition from MK progenitors to mature MKs is characterized by a 
significant level of overlap, which gives rise to a population of cells known a pro-
megakaryoblast and the more mature diploid MK progenitors (megakaryoblasts) with 
increasing ploidy through a unique process known as “endomitosis” and decreasing 
proliferative potential40-41. This leads to the formation of pro-MKs, which contains a 
lobulated nucleus, polychromatic cytoplasm and developing granules39. Subsequently, 
MK undergoes terminal maturation, which is characterized by 2 morphological forms. 
The earlier mature MK is characterized by a low ratio of nuclear to cytoplasmic matter 
and a loss of basophilic staining of the cytoplasm42. The latter stage involves the 
formation of proplatelets and circulating platelets from large, granular and polyploid 
mature MKs by acquisition of the cytoplasmic structural and functional characteristics 
necessary for platelet action. 
 
1.1.2.1 Immunophenotypical identification of megakaryocytes 
 
MKs constitute a unique system of hematopoietic cell differentiation characterized by 
polyploidization, maturation and organized fragmentation of the cytoplasm leading to 
the release of platelets in the blood stream43. Platelets, the enucleated fragments of 
MKs, are critical in the maintenance of vascular integrity and also contribute to wound 
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healing, angiogenesis, and innate immunity. The analysis of MK cellular differentiation 
markers is useful in studies investigating megakaryopoiesis in normal and disease state. 
However, measurement of MK frequency, ploidy distribution, and maturation stage has 
been complicated by the fragility of MKs as well as inherent tendency to aggregate. 
Flow cytometry has been shown to be a sensitive, rapid and useful technique for the 
analysis of marrow MK cellular and molecular characteristics such as cell size, 
complexity of cytoplasm architecture, ability to undergo endomitotic cycles and 
expression of individual molecular markers44. Thus, the introduction of flow cytometry 
represents a significant technical advance in studies of MKs overcoming many of the 
technical limitations associated with separation and discrimination between MK 
maturation subsets.   
 Evaluation of precursors and mature cells in the MK lineage based on the 
expression of cell surface markers of MK differentiation and cell surface glycoprotein 
receptors that are essential for platelet function is outlined in Table 1.2. In humans, MK 
development commences with myeloid progenitors found within the c-Kit+Sca-1 Lin  
population which can be subfractionated with CD34 and FcγRII/III (FcγR) markers into 
CMPs and MEPs45. CMPs are identified as c-Kit+Sca-1 Lin CD34+FcγRlo and MEPs as 
c-Kit+Sca-1 Lin CD34 FcγRlo. The early commitment of primitive progenitors toward 
MK lineage, MK progenitors are marked by an increase in CD9 (tetraspanin) and CD41 
(GPIIb or integrin αIIb) within the MK differentiation pathway as                                        
c-Kit+Sca-1 Lin CD34 FcγRloCD9+CD41hi immunophenotype46. The degree of MK 
differentiation can be monitored by analyzing the expression phenotype of early    
(CD61, GP11b/IIIa complex) and late (CD42b, GPIb) markers of MK differentiation47. 
Immature MKs are defined as c-Kit+Sca-1 Lin CD34 FcγRloCD9+CD41hiCD61hi,  
while mature functional MKs are identified as                                                                           
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c-Kit+Sca-1 Lin CD34 FcγRloCD9+CD41hiCD61hiCD42bhi 47,48. Expression of von 
Willebrand factor (vWF)49-50 and acetylcholinesterase staining51 is in concordance with 
MK maturation, whereas the expression of human leukocyte antigen (HLA)-DR 
declined with maturation and become negative in platelets49. 
 It is important to emphasize that CD41/CD61 were thought to be an integrin 
specific and selective phenotypic markers for the MK/platelet lineage52, these markers 
should be used with caution in identifying MK cells as there is increasing evidence that 
CD41 expression is not restricted to cells with potential to differentiate into MK   
cells53-56, but also in hematopoietic stem and progenitor cells (HSPCs) with a myeloid 
and lymphoid potential57.  
 
 
Table 1.2: Summary cell surface phenotypes of hematopoietic progenitors, 




Abbreviations: MK, megakaryocyte; HSC, hematopoietic stem cell; Lin, Lineage 
marker including IL-7R; FcγR, Fc-gamma receptor II/III; CMP, common myeloid 
progenitor; MEP, megakaryocyte/erythrocyte progenitor; lo, low expression; hi, high 













1.1.3 Endomitosis and proplatelet formation 
 
Endomitosis, also called endoreduplication of megakaryoblasts, is a TPO-driven 
process in which a series of recurrent cycles of DNA replication occurs without 
cytokinesis58-59 (Figure 1.4). During differentiation of megakaryocytic cells, the 
phenomenon of nuclear polyploidization allows megakaryocytes to accumulate DNA 
content ranging from 8N to 128N in a single poly-lobulated nucleus as well as 
facilitates the massive protein and lipid synthesis to create the invaginated membrane 
system (IMS) required for proplatelet formation60. The mechanism of endomitosis is 
poorly characterized. 
  The hypothesis that up-regulation of G1-phase components may be important in 
promoting cycles of endomitotic DNA synthesis to allow for the development of high 
ploidy MKs has been supported by multiple studies that have identified roles for G1/S-
phase regulators such as the cyclins D and E in endomitosis61-63, while studies in MK-
transformed cell lines showed that the switch to polyploidization is dependent on 
degradation of cyclin B and reduced activity of the cyclin-B-dependent Cdc2 kinase64-
66. Subsequent studies with primary MKs revealed that endomitosis occurs because of a 
defect in late cytokinesis that results in incomplete formation of the cleavage furrow, 
which is a contractile ring consisting of myosin II and F-actin that generates the 
mechanical forces necessary for cell separation67-68. Cleavage furrow inhibition in 
polyploidization may be due to the failure in RhoA (a small GTPase that regulates the 





Following nuclear polyploidization, MKs undergo cytoplasmic maturation 
involving the formation of IMS, which is an extensive complex of cisternae and tubules 
distributed throughout the MK cytoplasm that is continuous with the plasma membrane 
and it is the origin of the proplatelet and platelet surface70-71. The exact mechanism of 
platelet formation from mature MKs has been proposed by 2 major contrasting models; 
namely cytoplasmic fragmentation model and proplatelet model72.  
According to the cytoplasmic fragmentation model, MKs travel from the bone 
marrow to the lung where platelets are released by a rupture of MK in the 
microvasculature73. In contrast, the proplatelet model predicts that terminally 
differentiated MKs in the bone marrow develop multiple branching processes that 
extend into the marrow sinusoids to release platelets into the circulation72,74. In support 
of the latter model, studies using live cell microscopy on cultured MKs showed that 
proplatelets are comprised of platelet-sized swellings in tandem arrays that are 
connected by thin cytoplasmic bridges75.  Proplatelet production has been observed in 
vivo by imaging proplatelets extending into the sinusoidal blood vessels of bone 
marrow and in vitro with MKs derived from murine fetal liver stem cells and human 
cell-derived MKs. However, there is still much to be revealed about what molecular 









           
Figure 1.4: Endomitosis and proplatelet formation. 
Flow chart depicts the proliferation and differentiation of MK progenitors, including the 
MEP, BFU-MK and CFU-MK, into platelet-producing mature MKs. During this 
process, MKs undergo endomitosis to increase their size and DNA content. In murine 
cells, the DNA content can increase up to 128N. Associated surface antigens/markers 
are shown as pink arrows to indicate the approximate stage in MK development at 
which they are expressed. Abbreviations: MEP, megakaryocyte/erythrocyte progenitor; 
MK, megakaryocyte; BFU-MK, burst forming units-megakaryocyte; CFU-MK, colony 
forming units-megakaryocyte. (Modified from ref 3). 
 
 
1.2 Transcription factors, cytokines and signaling pathways associated 
with megakaryopoiesis 
 
Transcription factors are a family of DNA binding proteins that recognize specific DNA 
sequence motifs such as DNA promoter sequence of a gene proximal to the 
transcription start site76-77, which interact with sets of transcription factors binding on a 
distal DNA element known as cis-regulatory elements and recruitment of RNA 
polymerases, leading to the initiation and modulation of transcriptional activation or 
repression78. Transcription factors also exert control over spatial and temporal 
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expression of target genes through combinatorial interactions with other transcription 
factors, co-factors, and chromatin-remodeling proteins.  
Transcription factors are shown to act as key regulators for the normal 
functioning of the hematopoietic system and hematopoietic lineage fate decision based 
on gene targeting experiments. However, the molecular roles of these transcription 
factors can be altered in the event of genetic perturbations, including mutations, 
chromosomal translocations or viral insertions either in the transcription factor 
sequence itself or in its cis-regulatory elements79. About 5-10% of genetic disorders 
results from germline point mutations in transcription factors of identified gene and 
although many of these mutations are rare, majority of them affect embryonic 
development which provided evidence of the importance of these transcription factors 
in early development80. Somatic mutations in transcription factors are also observed in 
38% and 44% of the genes involved in chromosomal abnormalities associated with 
hematopoietic and solid tumors respectively81.  
The consequences of mutations in transcription factors are (i) gene dosage effect 
resulting in haploinsufficiency of the transcription factor function, (ii) the mutant can 
act as a dominant negative and interfere with the wild type transcription factor, or (iii) 
generation of gain-of-function mutants, especially if the mutation is in an inhibitory 
domain of the protein. 
Cytokines are a large family of specific extracellular ligands produced by 
diverse cell types, which can act systematically via the bloodstream or lymphatic 
vessels or locally within the microenvironment of HSPCs. These cytokines play key 
roles in mediating hematopoietic differentiation during steady-state and its adaptation 
upon inflammation or injury.  Cytokines of the hematopoietic system include 
interleukins (ILs), colony-stimulating factors (CSFs), interferons, erythropoietin (EPO) 
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and thrombopoietin (TPO). Cytokines signal by binding to, and activating, a family of 
structurally and functionally conserved cytokine receptors, which can be composed of 
dimers of a single receptor [granulocyte-CSF receptor (G-CSFR), EPO receptor 
(EPOR), TPO receptor (c-MPL)] or can be heterodimeric with a common signaling 
subunit and a unique ligand-binding chain.  
In addition to transcription factors, there is accumulating evidence that some, 
but not all cytokine receptors can transduce a genuine lineage-determining signal at 
some points in hematopoiesis, especially at the point of divergence of the myeloid and 
lymphoid lineages82. 
Understanding of the molecular basis of megakaryopoiesis has progressed 
substantially since the discovery of the production of platelets by MKs. Regulation of 
megakaryopoiesis is tightly controlled by an intricate regulation of a myriad of 
signaling pathways whereby a complex network of hematopoietic growth factors are 
involved in either a TPO-dependent signaling or a TPO-independent signaling83. 
Despite great advances, the precise cell-signaling events underlying the regulation of 
megakaryopoiesis are as yet not well understood.   
 
1.2.1 Transcriptional regulation in normal and malignant megakaryopoiesis 
 
Combination of transcriptional regulatory proteins have been shown to play an essential 
role in MK development as binding of a single transcription factor most likely 
insufficient to regulate megakaryopoiesis, which requires corresponding activation of 
MK-specific gene and effective inhibition of erythroid differentiation by lineage-
specific transcription factors such as GATA-1, RUNX1/AML1, SCL, ETS family 
members, GFI-1B and NF-E2.  
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Generation of gene-targeted mice involving critical factors such as Runx1 and 
Scl results in embryonic lethality, which hinders the understanding of the role of these 
factors in adult megakaryopoiesis. More recently, conditional knockout (KO) mice 
provide experimental systems to overcome such technical problems. Table 1.3 
summarizes the results obtained from studies of selected transcription factors which are 
involved in normal adult megakaryopoiesis. 
 
Table 1.3: Expression of transcription factors involved in normal adult 
megakaryopoiesis and KO phenotypes.  
 
 
Abbreviations: KO, knockout; HSC, hematopoietic stem cell; LT-HSC, long-term HSC; 
ST-HSC, short-term HSC; MPP, multipotent progenitor; MEP, 
megakaryocyte/erythrocyte progenitor; MKs, megakaryocytes; HSPC, hematopoietic 








The X-linked gene GATA-1 is a transcription factor containing two phylogenetically 
conserved zinc fingers (known as the N-finger and the C-finger), whereby the C-finger 
recognizes and binds to the consensus “WGATAR” sequence in the cis-regulatory 
elements of many lineage-restricted genes87-89, and the N-finger increases the affinity of 
GATA-1 binding to complex, palindromic sites and recruits co-factors such as Friend of 
GATA-1 (FOG-1). FOG-1 is a large multifinger protein that interacts with GATA-1 to 
mediate the terminal maturation of MKs as well as proplatelet formation, and FOG-1 
deficient mice lack MKs, supporting a critical role in early MK development90,91. 
Tissue-specific expression of GATA-1 gene employs two alternative promoters, namely 
the distal (IT) promoter for hematopoietic cells92,93 and the proximal (IE) promoter for 
testis94-95. 
GATA-1 has been shown to be critical for the development of erythroid and 
megakaryocytic lineages, suppressing the proliferation of megakaryocytic and erythroid 
precursors while promoting their differentiation85. Several studies have confirmed the 
findings that acquired mutations within exon 2 (or the intron immediately downstream) 
of GATA-1 are detected in both transient myeloproliferative disorder (TAM) and Down 
syndrome-associated acute megakaryoblastic leukemia (DS-AMKL), which results in 
an alternative 40 kDa translation product (referred to as GATA-1s) that lacks the N-
terminal transactivation domain and initiates translation at methionine at amino acid 84 
in exon 3, thereby preventing the synthesis of the 50 kDa full- length GATA-196-100 
(Figure 1.5). GATA-1s still promoted terminal differentiation of MKs although fetal 
liver megakaryopoiesis was hyper-proliferated101. Mutagenesis of GATA-1 is an early 
event in DS leukemogenesis but it has been shown to be insufficient for overt leukemia.  
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Figure 1.5: Models for the expression of GATA-1 isoforms. 
Schematic diagram illustrates the translation of GATA-1 protein from the GATA-1 
mRNA only, whereas the translation of GATA-1s protein either from the GATA-1 
mRNA or from the alternative spliced GATA-1s mRNA lacking exon 2 due to short 
nucleotide insertions, deletions or missense or nonsense mutations that lead to the 
introduction of a premature stop codon. Abbreviations: N-ZF, amino-terminal zinc-
finger domain; C-ZF, carboxy-terminal zinc-finger domain; NLS, nuclear localization 






The RUNX1 (Runt-related transcription factor 1) gene encodes the DNA-binding α-
subunit of the heterodimeric Polyomavirus enhancer binding protein 2/Core binding 
factor (PEBP2/CBF) complex, known to play a critical role in hematopoietic stem cell 
and MK development104-106. RUNX1 has been shown to be the most frequently mutated 
gene in human leukemia, in which it has been implicated in over 30 different 
translocations, and was first identified in chromosomal rearrangements observed in 
patients with AML and hence RUNX1 is also called AML1107. Interestingly, RUNX1 is 
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located within the critical region of chromosome 21 that is responsible for clinical 
manifestations of DS108. The RUNX genes have an evolutionarily conserved 128-amino 
acid Runt domain required for DNA-binding at consensus DNA-binding sites 
(Pu/TACCPuCA) and heterodimerization with the β subunit104 (Figure 1.6).  
 
Figure 1.6: A diagrammatic representation of RUNX1. 
Normal RUNX gene expressed from two promoters (P1 or distal, and P2 or proximal), 
The Runt domain is the most conserved feature of the proteins, as well as a nuclear-
matrix-targeting signal (NMTS) and the carboxy-terminal VWRPY motif. 
Abbreviations: aa, amino acid. (Modified from ref 109).  
 
 
Haploinsufficiency of RUNX1 causes familial platelet disorder (FPD) with a 
predisposition to AML in human, exhibiting mild thrombocytopenia and platelet 
abnormalities including diminished dense core granules and decreased cellular 
adenosine diphosphate (ADP) levels110. Adequate expression of RUNX1 is essential for 
normal platelet homeostasis, as Runx1-heterozygous animals display mid 
thrombocytopenia and a decrease in long-term repopulating hematopoietic stem cells. 
Diminished RUNX1 function leads to a significant decrease in polyploidization and 
terminal maturation of MKs as well as platelet formation in vivo111.  
Gene targeting of Runx1 in mice also demonstrates that MK differentiation is 
sensitive to Runx1 dosage. RUNX1 expression is elevated in human fetal livers with 
trisomy 21112,113. Moreover, transgenic mice which overexpress RUNX1 exhibited a 
transient increase of MK surface marker CD61+ myeloid cells in neonates114. Therefore, 
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the increased RUNX1 expression at fetal stage may be one of the mechanisms 
accounting for the abnormal megakaryopoiesis in DS patients. 
 
1.2.1.3 Other megakaryocyte-selective transcription factors 
 
The role of basic helix-loop-helix protein stem cell leukemia (SCL)/ T-cell acute 
lymphoblastic leukemia gene 1 (TAL1) in early hematopoietic progenitors for 
specification of the megakaryocytic lineage115 is well established with loss-of-function 
studies showing a requirement for SCL in the development of fetal liver 
megakaryopoiesis116-117. Analysis of conditional Scl-knockout mice in hematopoietic 
cells revealed perturbation of megakaryopoiesis and erythropoiesis with a loss of early 
progenitor cells in both lineages. Long-term defects in Scl-deleted bone marrow cells in 
adult mice also revealed a late defect in MK differentiation under stress conditions 
leading to defective platelet production118. SCL exerts its activity as part of a large 
pentameric complex, along with E47, LMO2, LDB1, and GATA-1 at all activating 
GATA-1 elements in MKs119. However, the function and transcriptional activity of Scl 
in megakaryopoiesis remained to be fully characterized.  
ETS family of a transcription factors is defined by a conserved winged helix-
loop-helix DNA binding (ETS) domain that allows recognition of purine-rich DNA 
sequences with a core GGA(A/T) consensus, designated EBS (ETS binding 
sequence)120. Several members of the ETS gene family of transcription factors such as 
GA-binding protein α (GABPα), ETS1, ETS2, Ets-related gene (ERG) and Friend 
leukemia integration 1 (Fli-1), play critical roles in megakaryopoiesis, which can 
function either as activators or repressors depending upon the specific promoter and 
cellular context3. The heterodimeric GA-binding protein (GABP) complex consist of 2 
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components whereby GABPα mediates DNA-binding and GABPβ required for 
transcriptional activation as well as nuclear localization of GABPα121-123. Notably, 
GABPα has been shown to function as a regulator of early MK-specific gene 
expression. Another member of the ETS family, Fli-1 is also necessary for the normal 
maturation of MKs and controls the expression of multiple MK-specific 
genes124,125. Moreover, the ratio of GABPα/Fli-1 expression declines throughout MK 
maturation, indicating that Fli-1 binds to promoters of both early and late MK-specific 
genes126. Expression of ETS1 was shown to increase during MK maturation and 
overexpression of ETS1 leads to enhanced differentiation as well as upregulation of 
GATA-2 and MK-specific genes127. ETS2 and ERG are encoded within the DS critical 
region on human chromosome 21 and are able to promote megakaryopoiesis 
independent of GATA-1128. In addition, specific collaboration of ETS2 and ERG with 
alterations in GATA-1 revealed to promote immortalization of fetal liver progenitors. 
The zinc finger transcriptional repressor, growth factor independence-1B (GFI-
1B) is essential for terminal MK maturation and Gfi-1b deficiency in fetal liver 
progenitors causes a reduction in proliferation concomitantly with an inhibition of 
differentiation of immature progenitors129. The basic region-leucine zipper DNA 
transcription factor of nuclear factor-erythroid 2 (NF-E2) is primarily essential for 
platelet biosynthesis by promoting the expression of mid-late stage MK genes including 
β1-tubulin as homozygous null NF-E2 mice revealed to have a defect in platelet 
production resulting in absolute thrombocytopenia130,131.  
Aberrant expression of these transcription factors are emphasized in abnormal 
megakaryopoiesis although further studies are necessary to define the contribution of 




1.2.2 Cytokines involved in the regulation of megakaryopoiesis 
 
Numerous pleiotropic cytokines are known to influence megakaryocyte development at 
different stages of the process such as TPO, IL-6 and IFN-γ. Although it is widely 
accepted that TPO is the primary regulator of megakaryopoiesis, the other 
megakaryocyte-active cytokines undoubtedly contribute to the regulation of this 
process.  
 
1.2.2.1 Thrombopoietin (TPO) 
 
While a number of cytokines have been associated with the process of 
megakaryopoiesis, the primary growth factor that has been isolated and identified to be 
responsible for the regulation of megakaryopoiesis and thrombopoiesis (which is a the 
process of formation of thrombocytes/platelets) is the hematopoietic cytokine, 
thrombopoietin (TPO). TPO exerts its function through binding and activation of the 
TPO receptor (c-Mpl), which is a type I transmembrane receptor predominantly 
expressed in hematopoietic tissues, hemangioblasts, MKs and platelets132,133. 
Human TPO, the main physiological regulator of megakaryopoiesis and 
thrombopoiesis, is produced constitutively by the liver6,134. TPO is encoded by a single 
human gene, located on chromosome 3q26.3-3q27, a region of the long arm of 
chromosome 3, which produces a 353 amino acid precursor protein and an acidic and 
heavily glycosylated 332 amino acid mature protein6. TPO avidly binds and activates 
the c-Mpl receptors on MKs and selectively initiates the proliferation and maturation of 
MK progenitor cells as well as stimulate the expression of characteristic cell surface 
proteins including CD61/41 (GpIIb/IIIa) and CD42 (Gp1b)135 in addition to inducing 
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endomitosis by creating the IMS required for proplatelet formation and cytoplasmic 
delivery of platelets into the circulation136,137. Regulation of megakaryopoiesis by 
plasma levels of unbound TPO reflects the balance between constitutive production and 
rate of destruction that is generally dictated by the overall platelet production6. Mice 
deficient in TPO or its ligand c-Mpl genes were shown to have severe 
thrombocytopenia with 10-20% residual platelet counts and reduction in progenitors 
committed to the MK lineage as well as functionally normal MKs138. Although these 
studies have underscored the importance of TPO in promoting the differentiation of 
HSCs into mature MKs, they also demonstrated that TPO is central but not essential for 
megakaryopoiesis and platelet release. 
 
1.2.2.2 Other cytokines involved in the regulation of megakaryopoiesis 
 
Interleukin-6 (IL-6) is a 26 kDa pleiotropic cytokine that has been shown to have 
various effects on MK development in vitro and in vivo. IL-6 primarily affects the later 
stages of megakaryopoiesis. IL-6 alone does not affect MK colony formation but 
synergizes with IL-3 or GM-CSF to increase the number, size, and DNA content of 
developing MKs139. Additionally, IL-6 acts as a differentiation-inducing factor required 
for full MK maturation140,141. Furthermore, administration of recombinant human IL-6 
to mice augmented the platelet counts accompanied by an increase in the size of their 
MKs142. Clinical studies of IL-6 have shown its stimulatory effects on thrombopoiesis 
in patients with myelodysplastic syndrome and that IL-6 increased the frequency of 
higher ploidy MKs but did not significantly increase the number of MK progenitor 
cells143. In another study, human soluble IL-6 receptor dose-dependently enhanced the 
generation of MK (CD41+ CD61+ cells) from human CD34+ cells in serum-free 
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suspension culture supplemented with IL-6 and SCF through glycoprotein (gp)130 
signaling144. 
Interferon-γ (IFN-γ) is a dimerized soluble cytokine of the type II class of 
interferons produced by activated T-cells and natural killer cells in response to viral 
infection or other stimuli145. IFN-γ has been shown to support megakaryopoiesis by 
promoting the development of MK progenitor, CFU-MK, under some conditions in 
vitro146 as well as in cultures of murine bone marrow cells supplemented with IFN-γ 
and SCF147. IFN-γ in combination with TPO and SCF significantly augmented the 
development of MK colonies and increased the DNA content of cultured MKs145. In 
addition, the marked increased in MK numbers were recapitulated in vivo and the 
recovery of platelets was facilitated by the administration of IFN-γ, in conjunction with 
IL-3. Moreover, effect of IFN-γ was observed to shortened the duration of 
thrombocytopenia in animals treated with 5-fluorouracil, whereas IL-3 alone had not 
effect148. IFN-γ was also found to support TPO-independent proliferation of human MK 
progenitor cells as the addition of anti-TPO polyclonal antibody almost completely 
abrogated TPO-dependent MK colony formation but failed to inhibit the generation of 
MK colonies induced by IFN-γ145. Therefore, several studies have denoted that IFN-γ 
plays a unique role as a positive regulator of the MK lineage. Taken together, these 
results suggest that additional megakaryocyte-active cytokines or other signals are 








1.2.3  Signaling pathways influencing megakaryocyte development 
 
Activation of JAK-STAT pathway through interaction of TPO with its receptor exerts 
significant influence on MK proliferation and differentiation. Also, Notch signaling has 
been found to inhibit megakaryopoiesis by suppressing the essential transcription factor 
GATA-1. I chose to pursue a candidate approach focusing on the JAK-STAT and Notch 
signaling pathways. 
 
1.2.3.1 JAK-STAT signaling pathway 
 
The evolutionarily conserved Janus kinase (JAK)-signal transducer and activator of 
transcription (STAT) signaling pathway is an intracellular signaling pathway that was 
originally discovered through studies on gene induction by interferons (IFNs) and 
mediates the effects of members of the cytokine receptor superfamily and growth 
factors, including those clinically important cytokines such as G-CSF, EPO, TPO, the 
interferons, and numerous interleukins149-151. JAK-STAT signaling pathway is essential 
for numerous developmental and homeostatic processes, including hematopoiesis, 
immune cell development, stem cell maintenance, organismal growth and mammary 









1.2.3.1.1 JAK structure and function 
 
JAKs, in reference to the two-faced Roman god, is a unique class of tyrosine kinases 
that contain two symmetrical kinase-like domains; the C-terminal JAK homology 1 
(JH1) domain possesses tyrosine kinase function while the adjoining JH2 domain is a 
catalytically inert, pseudo-kinase domain which may regulate kinase activity of 
JAKs153-154. In mammals, there are four members of the JAK family, namely, JAK1, 
JAK2, JAK3 and tyrosine kinase 2 (TYK2) and they all contain seven JH domains 
organized into four regions; kinase (JH1), pseudo-kinase (JH2), FERM (band-4.1, ezrin, 
radixin, and moesin) which consists of the N-terminal JH7, JH6, JH5 and part of JH4, 
and SH2 (Src Homology 2)-like which consists of JH3 and part of JH4151,155 (Figure 
1.7). Expression of JAK1, JAK2 and Tyk2 is ubiquitous; however expression of JAK3 
is restricted to hematopoietic cells156,157. Several specific hematopoietic cytokines 
activate JAK2 in normal megakaryocyte precursors and megakaryocytic cell lines for 
megakaryocytic cell proliferation158,159. The critical roles of JAK proteins in 
hematopoietic ontogeny have been clearly demonstrated via targeted gene disruption 
studies in mice (Table 1.4). Loss of Jak1, Jak3, or Tyk2 results in impaired 
lymphopoiesis, whereas Jak2 deficiency results in embryonic lethality as a result of 










Figure 1.7: Domain structure of Janus kinases (JAKs). 
JH1 is the kinase domain containing two tyrosines that can be phosphorylated after 
ligand stimulation. JH2 is the pseudo-kinase domain. JAKs have an Src homology 2 
(SH2) domain and the amino terminus of JAKs (JH5-JH7) has homology to the band 
four-point-one, ezrin, radixin, moesin (FERM)-domain containing proteins. The JH6 




Table 1.4: Gene targeting studies on Janus kinases (JAKs) family members. 
Abbreviations: Jak1-3, Janus kinase 1-3; IL, interleukin; LIF, leukemia inhibitory 
factor; OSM, oncostatin M; GM-CSF, granulocyte-macrophage colony-stimulating 
factor; EPO, erythropoietin; TPO, thrombopoietin; IFN, interferon; SCID, severe 






1.2.3.1.2 STAT structure and function  
 
Signal transducer and activator of transcription (STAT) proteins are a 7-member 
mammalian family of latent cytoplasmic transcription factors (STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, and STAT6)170 which is highly homologous in several 
regions, including a SH2 domain involved in the activation and dimerization of 
STATs171,172, a DNA-binding domain173, and a transactivation domain located at the 
carboxyl terminus174,175 whereas the amino-terminal region of STATs is involved in 
regulating STAT activity such as the formation of STAT tetramers176 and tyrosine 
dephosphorylation177 (Figure 1.8). The critical roles of STAT proteins in hematopoietic 
ontogeny have been clearly demonstrated via targeted gene disruption studies in mice 
(Table 1.5). Mice lacking Stat1, Stat2, Stat4, or Stat6 are viable but exhibit specific 
signaling abnormalities, predominantly in lymphoid cells159. Stat3 deficiency results in 
early embryonic lethality as a result of severe developmental defects, and simultaneous 














Figure 1.8: Linear representations of the domain structures of the signal 
transducer and activator of transcription (STAT) protein family.  
The amino-terminal domain mediates the interaction between two STAT dimmers to 
form a tetramer, whereas the coiled-coil domain is involved in interactions with 
regulatory proteins and other transcription factors. The DNA-binding domain makes 
direct contact with STAT-binding sites in gene promoters. Reciprocal interactions 
between the SH2 domain of one STAT monomer and the phosphotyrosine residue of 
another mediate dimer formation, which is required for the binding of STATs to DNA. 
The transactivation domain is involved in the transcriptional activation of target genes 
through interactions with other proteins. The carboxy-terminal domain contains a site of 
serine phosphorylation that enhances transcriptional activity in some STATs. The 
activity of STATs can be regulated by protein modification, including tyrosine and 
serine phosphorylation, methylation, sumoylation, ISGylation and acetylation. The 
modification sites of ISGylation and acetylation have not been identified. 




















Table 1.5: Gene targeting studies on signal transducer and activator of 
transcription (STAT) family members. 
 
 
Abbreviations: IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating 
factor; G-CSF, granulocyte colony-stimulating factor; Th1, T helper. (Adapted from 
refs 150,151,179-191).  
 
 
1.2.3.1.3 Mechanism of JAK-STAT signaling 
 
Members of the type I and type II cytokine receptor families often employ JAK family 
of tyrosine kinases to phosphorylate and activate downstream proteins involved in their 
signal transduction pathways as these receptors lack intrinsic catalytic kinase activity 
(Figure 1.9). Intracellular activation occurs when ligand binding induces the 
multimerization of receptor subunits. For some ligands, such as EPO and growth 
hormone, the receptor subunits are bound as homodimers while, for others, such as 
IFNs and interleukins, the receptors subunits are heteromultimers192. For signal 
dissemination through either homodimers or heteromultimers, the cytoplasmic domains 
of two receptor subunits must be associated with JAK tyrosine kinases. Cytokine 
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stimulation leading to JAK activation results in the tyrosine phosphorylation of the 
cytoplasmic domain of the receptor generating docking site(s) for STAT SH2 
domains193.  
Once recruited to the receptor-JAK complex, STATs are tyrosine 
phosphorylated at the C-terminus by JAKs, leading to the formation of STAT 
homodimers or heterodimers via SH2 domain-phosphotyrosine interactions194. 
Following dimerization, STATs rapidly translocate into the nucleus by a mechanism 
that is dependent on importin α-5 (also called nucleoprotein interactor 1) and the Ran 
nuclear import pathway195. Once in the nucleus, dimerized STATs interact and bind 
specific regulatory elements to induce target gene transcription that stimulates several 
cellular events such as cell proliferation, differentiation, cell migration and apoptosis196.  
The termination of STAT signaling is due to a number of different factors, 
including receptor degradation via the lysosome and proteasome, activation of cellular 
phosphatases and expression and activation of specific regulatory proteins197. There are 
three major classes of negative regulator: SOCS (suppressors of cytokine signaling) 
which can either bind to phosphotyrosines on the receptors or bind directly to JAKs 
and/or receptors or interact with the elongin BC complex SAP (SAF-A/Acinus/PIAS) 
domain at the N-terminus198; PIAS (protein inhibitors of activated stats) which bind to 
activated STAT dimmers and prevent them from binding DNA192; PTPs (protein 































1.2.3.1.4 Implications of JAK-STAT signaling in hematological malignancies 
 
Genetic alterations affecting members of the JAK family, causing aberrant JAK-STAT 
signaling and constitutive STAT activation have been discovered in a wide array of 
cancers and are particularly prominent in hematological malignancies. Mutations in 
JAK family members is increasingly recognized with the discovery of the V617F 
mutation in JAK2 in a substantial proportion of patients with chronic myeloproliferative 
neoplasms (MPNs), a spectrum of neoplastic disorders characterized by overproduction 
of terminally differentiated cells of the myelo-erythroid lineage and share a 
predisposition to the development of AML202-205. Additionally, rare variants in exons 12 
to 15 have also been identified in patients with MPNs206. 
Recently, point mutations that activate JAK family members have also been 
revealed to be common in acute leukemias. Acquired lesions involving JAK1, JAK2, 
                
Figure 1.9: Schematic representation 
of the JAK-STAT pathway. 
Ligand-induced receptor oligomerization 
activates JAKs that subsequently 
phosphorylate tyrosine residues on the 
cytoplasmic portion of the receptor. The 
quiescent STAT monomers are then 
recruited to the activated receptor 
complex via the interaction of the SH2 
domains with phosphotyrosine docking 
sites. STATs are phosphorylated by the 
JAKs on a conserved tyrosine residue in 
the c-terminal domain to form STAT 
homodimers or heterodimers. STATs 
dissociate from the receptor after the 
dimerization and translocate into the 
nucleus. In the nucleus, STATs bind to 
specific response elements and induce 




and JAK3 (but not TYK2) as well as several analogous JAK2 fusion proteins have been 
reported in both AML and ALL. More importantly, several non-recurrent JAK3 
mutations were identified in the CMK megakaryoblastic cell line and patients with 
AMKL207, while JAK3 mutations are rare in ALL and AML. Several different JAK3 
mutations (I87T, P132T, A572T, A573V, M576L, A593T and V722I) have also been 
reported in primary AMKL samples but are yet to be functionally characterized208-210. 
Although only the A572V and V722I mutants are found to be situated within the 
pseudokinase domain and P132T mutation lies within the receptor binding region of 
JAK3, all three mutations were found to constitutively activate the JAK3 protein.  
Constitutive activation of STAT3 and STAT5 has been linked with disease 
outcomes in AML demonstrated by analyses of primary peripheral blood and bone 
marrow specimens197. Additionally, AML patients with STAT3 polymorphism were 
found to be associated with unfavorable cytogenetics and failure to achieve complete 
remission211. Constitutive activation of STAT5 has also been associated poor overall 













1.2.3.2 Notch signaling pathway 
 
The Notch gene was first described on mutant Notch phenotypes of fruit flies 
(Drosophila melanogaster) in 1914, and, rapidly thereafter, identification of mutant 
alleles with the observation of a Drosophila strain with notched wings212. However, it 
was not until after the molecular biology revolution that the Notch receptor was cloned 
and the wing-notching phenotype was attributable to gene haploinsufficiency213,214.  
Notch signaling is a highly evolutionary conserved pathway, which plays 
pleiotropic roles during embryogenesis and is important for the regulation of self-
renewing tissues of adult organism215. The physiological functions of this signaling 
cascade include maintenance of stem cells, determination of cell fates and regulation of 
cell proliferation, differentiation as well as apoptosis. Notch signaling has also multiple 
functions during normal lymphoid development, which include regulation of T-cell 
commitment from a multipotential precursor, regulation of αβ T-cell development, and 
marginal zone B-cell development216. However, the function of Notch signaling in the 
development of myeloid cells including megakaryocytes is still not well defined. 
Although Notch signaling has mostly been associated with oncogenic and 
growth-promoting roles, there is growing evidence that components of the same 









1.2.3.2.1 Notch receptors and ligands 
 
The human NOTCH family includes four distinct receptors (NOTCH 1-4) and five 
canonical ligands which include 3 Delta-like ligands (DLL1, DLL3 and DLL4) and 2 
Jagged ligands (JAG 1 and 2)215,218,219. NOTCH receptors are expressed at the cell 
surface as heterodimers comprising an extracellular subunit (NEC), which linked to a 
second subunit containing the extracellular heterodimerization domain (HD) followed 
by a transmembrane domain and the cytoplasmic region of the receptors (NTM) which 
also contains the intracellular domain of NOTCH (NICD). The extracellular domains of 
NOTCH1 and NOTCH2 each have 36 epidermal growth factor (EGF)-like repeats, 
while NOTCH3 harbours 34 and NOTCH4 contains 29 repeats220 (Figure 1.10). EGF-
like repeats is required for efficient binding of receptors to ligands and therefore, 
differences in the number of EGF-like repeats between NOTCH receptors may be 
significant because EGF-like repeats are fucosylated on specific serine and threonine 
residues by O-fucosyltransferase221-223. Modifications of these O-fucose moieties by the 
addition of N-acetylglucosamine by the Fringe family of 1, 3 N-
acetylglucosaminyltransferases223 subsequently regulate the affinity of NOTCH 
receptors for certain ligands225,226. NEC also contains a juxtamembrane negative 
regulatory region (NRR) consisting of three cysteine-rich LIN12/NOTCH repeats that 
prevent ligand-independent signaling and a HD227 which is a C-terminal hydrophobic 
region mediating heterodimerization between NEC and NTM 228. The NICD consists of 
seven ankyrin repeats which are essential for the formation of the transcriptional 
activation complex and the recruitment of a member of the mammalian Mastermind-
like proteins (MAML1-3) MAML1229, a transactivation domain (TAD), a nuclear 
localization signal (NLS), and a proline-glutamate-serine-threonine-rich (PEST) domain 
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regulating protein stability229-231. Other differences are found within the NICD; 
specifically, NOTCH1 contains a strong TAD and NOTCH2 a weak TAD, but 
NOTCH3 and NOTCH4 lack TAD, influencing promoter selectivity at least in 
vitro220,232. NOTCH ligands are transmembrane proteins of which the extracellular 
domain contains a characteristic number of EGF-like repeats and a cysteine rich N-
terminal Delta/Serrate/LAG-2 (DSL) domain, responsible for the interaction with 
NOTCH receptors233,234.  
 
Figure 1.10: Domain organization of the human NOTCH receptors and ligands. 
There are four Notch receptors, NOTCH1 to NOTCH4 in mammals and classical 
NOTCH ligands including JAG1 and 2 as well as Delta-like ligands DLL1, 3 and 4. 
Abbreviations: EGF-like repeats, epidermal growth factor-like repeats; LIN, negative 
regulatory LIN repeats; HD, heterodimerization domain; NRR, negative regulatory 
region; TM, transmembrane domain; RAM, RBPJ associated molecule domain; NLS, 
nuclear localization signal;  ANK, ankyrin repeats; TAD, transactivation domain; 
PEST, proline-glutamate-serine-threonine-rich domain; CR, cysteine rich domain; DSL, 
Delta, Serrate and LAG-2 domain. S1, S2 and S3 indicate the crucial proteolytic sites. 








1.2.3.2.2 Regulatory mechanism of Notch signaling 
 
Notch receptors are single pass type I transmembrane receptors translated as a single 
polypeptide that is cleaved during post-translational modification in trans-Golgi 
vesicles by a furin-like convertase (S1 cleavage) and exist as a non-covalently linked 
heterodimer at the cell surface236. Canonical Notch signaling pathway, which is the 
most extensively characterized signaling pathway237, is initiated by binding of the 
Notch transmembrane receptors with their specific ligands between two neighbouring 
cells, leading to two rapid consecutive proteolytic cleavages215 (Figure 1.11). The first 
(S2) cleavage occurs extracellularly in the HD mediated by ADAM (a disintegrin and 
metalloprotease) family, ADAM10 or TACE (TNF-α converting enzyme, also known 
as ADAM17)238,239, followed by a mono-ubiquitination process240 and eventually 
generates the substrate for the S3 cleavage by the γ-secretase complex, which is 
composed of Presenilin, APH1, PEN2, and Nicastrin (NCSTN)241.  Subsequent 
proteolytic cleavage of S3 liberates the NICD of the receptor which then translocates to 
the nucleus242,243.  
Canonical Notch signaling requires the formation of a complex with a 
transcription factor CSL (CBF1/Suppressor of Hairless/LAG-1) family DNA-binding 
protein {C promoter-binding factor 1 (CBF1) is also known as recombination signal 
binding protein for immunoglobulin J region (RBPJ) or kappa-binding factor 2 (KBF2( 
in mammals, as Suppressor of Hairless [Su(H)] in flies and Longevity-assurance gene-1 
(LAG-1) in C. elegans} and initiates the transcription of Notch target genes244. In the 
absence of receptor activation and NICD, RBPJ acts as a transcriptional repressor by 
binding DNA in a sequence-specific manner of several co-repressors including 
SMRT/NcoR, SHARP (or MINT), CtBP1 and SIRT1, which recruit histone 
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deacetylases and the histone demethylase LSD1245-248. Human SHARP (MINT for 
murine) belongs to the evolutionarily conserved Split ends (SPEN) gene family249. 
Upon entering the nucleus, NICD competes and displaces the co-repressor complex, 
consequently interacts and binds to CSL and mediates their conversion to a 
transcriptional activator followed by the recruitment of the coactivators protein 
MAML1 and histone acetyltransferases such as p300 to create a short-lived 
transcriptional activation complex244. 
Apart from the canonical Notch signaling, there are also other types of non-
canonical Notch signaling that can be initiated by a non-canonical ligand, or may not 
require cleavage of the Notch receptor233. The first one involves Notch ligation and 
translocation of activation signals independent of CBF1 (NICD-dependent), the second 
involves activation of Notch target genes that are independent of γ-secretase cleavage 
(NICD- and CBF1-indepedent) and the third involves CBF1-dependent gene activation 
without receptor cleavage and NICD release250. Additional non-canonical functions 
have been characterized such as regulation of actin cytoskeleton and interactions with 
Wnt signaling251. 
Termination of Notch signaling can occur at or downstream of the Notch 
receptor250. The Notch receptor can be degraded through the lysosomes by the ubiquitin 
ligase Itch/AIP4 or Nedd4, which act together with Numb and Itch/AIP4 to stimulate 
endocytosis and lysosomal degradation of the Notch receptor. The binding of Notch on 
DNA appears to be a quick and vibrant process controlled by the kinase CDK8 and the 
ubiquitin ligase FBXW7, followed by phosphorylation, ubiquitination, and proteasomal 
degradation of Notch, which abolished the Notch induced transcriptional activation252. 
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Figure 1.11: Schematic diagram showing canonical Notch signaling. 
Notch signaling is initiated by the ligand (DLL 1, 3, 4; JAG 1 and 2) engagement of the 
Notch (NOTCH1-4) receptor. The intracellular domain of Notch goes into the nucleus 
to a transcriptional repressor RBPJ which displaces the co-repressor complex and 
activates the expression of the Notch target genes. S1, S2 and S3 indicate the crucial 
proteolytic sites. Abbreviations: DLL, Delta-like; RBP-J, recombination signal binding 




1.2.3.2.3 Notch target genes 
 
Considering the number of developmental processes regulated by Notch, it was a 
surprised that only few target genes of Notch have been identified to date. The most 
extensively studied and best understood Notch target genes are two families of basic 
helix-loop-helix transcription factors: Hes (Hairy enhancer of split genes) and Hey 
(Hairy/enhancer of split related genes with YRPW motif) family254,255. These 
transcription factors function as transcriptional repressors and play an important role in 
development. Seven Hes (Hes1-7) and three Hey (Hey1,2 and L) genes have been 
identified in the mouse genome, but only Hes1, Hes5 and Hes7 as well as all Hey genes 
are induced by Notch activation. 
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Other studies have shown that CD25 and the transcription factor GATA3 are 
direct Notch target genes activated in T-cell development256. Additionally, two other 
Notch target genes NRARP (Notch-regulated ankyrin repeat protein) and Deltex1 are 
shown to be negative regulators of Notch signaling257. Further Notch targets are cyclin 
D1, c-myc, p21, p27, Akt, mTOR, VEGF and many more target genes of Notch 
signaling remained to be determined234,258.  
 
1.2.3.2.4 Implications of Notch signaling in hematological malignancies 
 
Notch signaling pathway has been shown to be genetically altered in various 
hematological malignancies, which can lead to either activation or repression of the 
pathway depending on the context and the activation status of other potentially 
oncogenic pathways. Several cases of hematological malignancies in which Notch has 
tumor suppressive (myeloid malignancies) or oncogenic (T cell acute lymphoblastic 
leukemia and chronic lymphocytic leukemia) roles are presented in Table 1.6. 
 




Abbreviations: T-ALL, T cell acute lymphoblastic leukemia; CLL, chronic lymphocytic 






1.2.3.2.4.1 Notch as an oncogene 
 
The importance of Notch signaling in lymphocyte development and oncogenic 
transformation has been well characterized. Notch1 has been shown to play an 
important role in directing T-cell lineage commitment at the expense of B-cell 
development as conditional deletion of Notch1 or Rbpj results in blocked T-cell 
development and the appearance of ectopic B cells in the thymus264,265. The first 
evidence for the involvement of Notch signaling in human cancer was the identification 
of a t(7;9)(q34;q34.4) translocation in T-cell acute lymphoblastic leukemia (T-ALL) 
patients resulting in a rearrangement between the intracellular part of NOTCH1 
(NICD1) and the T cell receptor beta (TCRβ) locus that leads to overexpression of 
truncated, constitutively active NOTCH1 in leukemia266. A crucial finding was the first 
activating NOTCH1 mutations in human T-ALL, occurring in approximately 56% of all 
cases, proving that NOTCH1 is a strong oncogenic allele260. Additionally, inactivating 
mutations or deletions were identified in the ubiquitin ligase FBXW7 and associated 
with sustained Notch signaling259,267-269. Subsequent animal modeling by other groups 
suggested that Notch1 mutations (“hot spots” of mutations in HD or PEST) are 
insufficient to induce disease but can collaborate with other oncogenic lesions such as 
KrasG12D to accelerate T-ALL, suggesting that NICD1 dosage is a crucial determinant 
in Notch oncogenicity270.  
Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults. 
Recently, NGS-based approaches have demonstrated that 10-12% of CLL cases exhibit 
activating mutations of NOTCH1 predicted to impair FBW7-induced NOTCH1 
degradation with the majority of patients harboring the same frameshift mutation 
(P2515Rfs*4), highlighting the significance of such mutations as a prognostic 
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marker261,262,271. In another study, mutational analysis of NOTCH1 was primarily found 
to occur more significantly in patients with the more clinically aggressive non-mutated 
IGV(H) subtype (20.4%) or in the high-risk Richter syndrome (31.0%) and in 
chemorefractory CLL (20.8%)244. These results including a very recent large-scale 
clinical analysis of CLL patients confirmed that NOTCH1 mutations are an adverse 
prognostic parameter in CLL and this appear to define a distinct high-risk clinical 
subtype for therapeutic intervention. 
After the discovery of its involvement in T-ALL, Notch signaling was also 
implicated in various solid tumors, including breast cancer, medulloblastoma, 
colorectral cancer, non-small cell lung carcinoma (NSCLC), and melanoma272, 
therefore it seems likely that the list of neoplasms involving some alteration in Notch 
signaling will continue to grow. 
 
1.2.3.2.4.2 Notch as a tumor suppressor 
 
In stark contrast to the oncogenic roles in the lymphoid compartment, there is growing 
evidence that components of the same oncogenic pathway in lymphocytes may have a 
growth-suppressive function in myeloid cells. Recently, a study has shown that 
conditional Notch loss-of-function through deletion of an indispensable component of 
the γ-secretase complex, NCSTN, or compound deletion of Notch1/2 in vivo led to the 
induction of chronic myelomonocytic leukemia (CMML)263, which is a disease 
classified as a myelodysplastic/ myeloproliferative overlap syndrome, characterized by 
increased extramedullary hematopoiesis, monocytosis, myeloproliferation, and frequent 
progression to acute myeloid leukemia (AML)244. Additionally, whole-transcriptome 
analysis revealed that Notch signaling regulates an extensive myelomonocytic-specific 
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gene signature, through the direct suppression of gene transcription by the Notch target 
gene Hes1262. Finally, novel somatic-inactivating Notch pathway mutations in NCSTN, 
MAML1, APH1A and NOTCH2 were identified in around 12% of CMML patients, 
which were unique as these mutations were not observed in other myeloproliferative 
disorders (MPD) such as polycythemia vera and myelofibrosis272. 
 
1.3 Megakaryoblastic leukemias 
 
Deregulation of any mechanisms mentioned in the previous sections causes MK-related 
human diseases such as platelet disorders, or leukemias. Acute leukemia is the most 
common pediatric malignancy, and the risk of developing leukemia in Down syndrome 
(DS) children with constitutional trisomy 21 is approximately 10-20-fold higher than in 
the general pediatric population274-276. Children with DS have a unique predilection to 
develop megakaryoblastic leukemias, including transient abnormal myelopoiesis 
[TAM, also known as transient myeloproliferative disorder (TMD)]277,278 and primary 
acute megakaryoblastic leukemia (AMKL)279. AMKL also occurs in adults much less 
frequently and is more likely to evolve as secondary AMKL from an antecedent 
idiopathic myelodysplasia or occurring after exposure to chemotherapeutic agents, such 




Figure 1.12: Stochastic model of leukemogenesis in Down’s syndrome. 
Flow chart depicts the multi-step leukemogenesis pointing at multiple effects of several 
trisomic human chromosome 21 (HSA21) genes. The HSA21 genes are shown in 
purple, measurable effects in red, multiple cell symbols signify hyperproliferation, cast 
dice symbols represent increased chance of mutagenic event occurring and the warning 
sign symbolizes an acquired mutation that has occurred. Abbreviations: ES, embryonic 
stem cells; HSC, hematopoietic stem cell; CMP, common myeloid progenitor; MEP, 
megakaryocyte/erythrocyte progenitor; CLP, common lymphoid progenitor; TMD, 
transient myeloproliferative disorder; AMKL, acute megakaryoblastic leukemia. 




1.3.1 Transient abnormal myelopoiesis (TAM) 
 
Approximately 10% of newborn infants with Down syndrome (DS) as well as 
phenotypically normal newborn infants with trisomy 21 mosaicism are born with 
TAM281, a preleukemic status characterized by the clonal expansion of myeloid cells 
including immature megakaryoblasts282.  
TAM shows a variety of clinical phenotypes, ranging from asymptomatic to 
causing perinatal death. Additional manifestations of TAM include cutaneous 
involvement, hyperviscosity, cardio-pulmonary syndrome with pleural and/or 
pericardial effusions, myelofibrosis, hepatomegaly and splenomegaly283. The majority 
of the affected infants with TAM are asymptomatic284-286; the probability of failure to 
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diagnose TAM in these asymptomatic cases raises the possibility that the true incidence 
of TAM is higher than currently assumed.  
Consequently, the diagnosis of TAM is confirmed most frequently by routine 
complete blood cell (CBC) analysis or from laboratory tests ordered for other 
reasons287. Peripheral blood characteristics of TAM are variable but typically involved 
varying percentages of circulating blasts, usually leukocytosis and thrombocytopenia 
and occasionally, basophilia. The morphology of blasts in TAM are usually large cells 
with finely stippled chromatin, 1 to 2 prominent nucleoli in amorphous nuclei, 
surrounded by small amount of basophilic cytoplasm and show foci of cytoplasmic 
azurophilic granules, appearance of cytoplasmic blebs which is a characteristic of 
megakaryoblasts, and, in contrast to other acute leukemias, are morphologically 
heterogenous and capable of infiltrating organs such as liver, heart and skin288. 
Flow cytometric immunophenotyping of TAM blasts show evidence of 
megakaryocyte differentiation and typically express CD45, CD33, CD38 and CD36; 
usually express CD34; variably express glycophorin A, CD41a (GP IIb/IIIa), CD42b 
(GP Ib), CD61, CD11b, CD13, human leukocyte antigen (HLA)-DR, CD7 and CD56; 
rarely express CD62 (p-selectin)281,288-291.   
The median age at diagnosis of TAM is 3-7 days292 and almost all cases 
presented within 2 months of birth according to data from three prospective studies of 
more than 200 newborn infants288,293,294. TAM in the majority of affected infants 
undergoes spontaneous remission within the first 3 months of life although over 10% of 
cases show hydrops fetalis, a serious condition characterized by severe edema in 
multiple body areas of a fetus or a newborn infant295,296. Up to 15% of cases with TAM 
show potentially fatal fulminant hepatic failure due to hepatic fibrosis and blast 
 47 
 
infiltration. Moreover, approximately 20-30% of DS infants with TAM subsequently 
develop full-blown AMKL within 3 years281,287,298-301.  
 
1.3.2 Acute megakaryoblastic leukemia (AMKL) 
 
Acute megakaryoblastic leukemia (AMKL) is a distinct subtype of acute myeloid 
leukemia (AML-M7) according to the French-American-British (FAB) classification302, 
diagnosed by the presence of at least 20% leukemic blasts in the bone marrow (BM) 
and by definition requires confirmation of megakaryocytic lineage in 50% or more of 
the leukemic blasts according to the World Health Organization (WHO) classification 
of hematopoietic neoplasms303 by studies of cell morphology and immunophenotyping.  
 Immunophenotypically AMKL blasts typically co-express stem/progenitor cell 
markers (CD34, CD33 and CD117), myeloid (CD33), megakaryocytic (CD41 and 
CD42b), and erythroid markers (CD36 and Glycophorin A) as well as the T cell marker 
(CD7)290,292,304,305. 
AMKL accounts for approximately 10% of pediatric AML, resulting in an 
incidence that is estimated to be 500-fold higher in children with Down syndrome (DS) 
than in the general pediatric population306. AMKL is divided into two major subgroups: 
AMKL arising in patients with Down syndrome (DS-AMKL), and leukemia arising in 
patients without Down syndrome (non-DS AMKL). DS-AMKL is generally associated 
with a very favourable prognosis, with an approximately 80% survival in contrast to the 
non-DS AMKL population, which has a 3 year survival of less than 40% despite high-
intensity chemotherapy279,307,308. Leukemic blast cell sensitivity to cytotoxic agents such 
as cytarabine (Ara-C) has attributes to some extent to the favourable outcome in 
patients with DS-AMKL309-311.   
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Combining conventional and molecular cytogenetic analyses such as G-banding, 
comparative genomic hybridization (CGH), and whole chromosome painting (WCP) 
defined recurrent clonal chromosomal abnormalities, which will aid in the identification 
of critical genes that are abnormal in AMKL cells312. Cytogenetic differences between 
DS and non-DS-AMKL include the absence of the translocation t(1;22), and instead, 
the presence of trisomies involving chromosome 1 and 8 as well as monosomy 7313. The 
most common abnormality detected by CGH that was not evident from conventional 
cytogenetic analysis was gain of chromosome 19 or arm19q, analyzed in both primary 
patient samples and megakaryoblastic cell lines312. Similarly, an approximately 20% 
incidence of chromosome 19 abnormalities with trisomy 19 occuring in 8 (16%) of 50 
patients lacking the Philadelphia chromosome was reported in another study280. Later, 
with analysis of larger database, it was recognized that nonrandom gain of chromosome 
19 and 21 noted in particular FAB AML-M7.   
Several studies have determined gene expression profiles by microarray analysis 
for DS or non-DS AMKL, which were typically limited to small group of samples due 
to the rarity of the AML-M7 subtype of leukemia and the criteria to limit the analysis to 
pediatric age. Therefore, an integrated quantitative transcriptome maps by systematic 
meta-analysis from available gene expression profile datasets related to AMKL in 
pediatric age was made possible by a recent approach using Transcriptome Mapper 
(TRAM) tool, providing the identification of genes relevant for the pathophysiology of 
AMKL which can potentially be new clinical markers314. Transcriptome map 
comparison of both DS and non-DS AMKL with normal MK has revealed three 
potential clinical markers of progression to AMKL: TMEM241 (transmembrane protein 
241) located on chromosome 18, which was the most over-expressed single gene; while 
APOPC2 (apolipoprotein C-II) and ZNF587B (zinc finger protein 587B), both located 
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on chromosome 19, appear to be the most discriminant markers of progression, 
specifically to DS AMKL314.  
 
1.3.2.1 Down syndrome-associated AMKL (DS-AMKL) 
 
The median age of onset of DS-AMKL is 1.8 years308.  Clinical and hematological 
features of DS-AMKL typically reveal anemia, marked thrombocytopenia and 
dysplastic changes in all myeloid lineages in the bone marrow, often accompanying 
marrow fibrosis before the development of overt AMKL292. Diagnosis of AMKL is 
confirmed by immunophenotyping of leukemic blasts with platelet-associated antigens. 
Identification of platelet peroxidase (PPO) activity using electron microscope (EM) is 
recommended by FAB classification315,316; however, it is not employed usually due to 
limited availability of EM. The morphology of blast cells appears to be less mature in 
patients with DS-AMKL than in those with non-DS AMKL317. 
The primary mechanistic basis for DS-AMKL is thought to involve increased 
gene dosage due to an additional copy of chromosome 21. Potential contribution of 
candidate genes located on chromosome 21 involved in DS-AMKL pathogenesis 
includes RUNX1 (also known as AML1), BACH1, ETS2 and ERG are mentioned in 
the previous Section 1.2.  
Non-chromosome 21 genes were shown to also contribute to DS-AMKL 
pathogenesis (discussed previously in Section 1.2). In particular, acquired mutations of 
the GATA-1 gene on chromosome X, a key transcription factor involved in erythroid 
and MK terminal maturation, were detected early at TAM stage and in almost all cases 
of DS-AMKL, which lead to a blockage of full-length transcript expression and 
production of the shorter variant GATA-1 isoform (GATA-1s) that lacks the N-terminal 
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transactivation domain of 83 amino acids100,318,319. Detection of identical GATA-1 
mutations in both TAM and DS-AMKL from sequential longitudinal samples from a 
single patient indicates that the DS-AMKL evolves from latent TAM clones that 
presumably persist following its clinical regression97. Interestingly, studies on the role 
of GATA-1 mutations in the transformation of MKs have shown that DS-AMKL cells 
express reduced levels of the GATA-1 target gene cytidine deaminase320, and as a 
consequence, these leukemic cells are hypersensitive to Ara-C chemotherapy resulting 
in their favourable outcome for a group of AMKL patients, with an overall survival of 
70-80% at 5 years310-311.  
 
1.3.2.2 Non-Down syndrome AMKL (non-DS AMKL) 
 
Non-DS AMKL patients appear to be more heterogeneous317 and molecular lesions that 
underlie this leukemia subtype remains elusive with the exception of the 
t(1;22)(p13;q13) detected in approximately one third of cases in infant non-DS 
AMKL321-322. The t(1;22)(p13;q13) occurs primarily during infancy (median age of 4 
months) showed hepatosplenomegaly and pronounced myelofibrosis. The translocation 
t(1;22)(p13;q13) results in the one twenty-two (OTT) [also known as RNA-binding 
motif protein-15 (RBM15)] gene located on 1p13 fused to the megakaryocytic acute 
leukemia (MAL) [also known as megakaryoblastic leukemia-1 (MLK1)] gene on 
chromosome 22 leading to the OTT-MAL [also known as RBM15-MLK1] fusion gene 
on the derivative 22. OTT (RBM15) contains several RNA recognition motifs and 
shows significant homology to the Drosophila protein spen, which regulates HOX 
homeotic function and neuronal cell fate. MAL (MLK1) contains a SAP (SAF-A/B, 
acinus, PIAS) DNA-binding domain and a coiled-coil domain, which presumably 
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mediates protein-protein interactions. The OTT-MAL (RBM15-MLK1) transcript 
encodes a chimeric protein containing all the functional domains of both partner 
proteins and thus, the OTT-MAL (RBM15-MLK1) potentially might deregulate RNA 
processing and possibly HOX signaling. The exact mechanism by which OTT-MAL 
(RBM15-MLK1) exerts its oncogenic properties remains unknown. 
Recently, a novel recurrent translocation involving CBFA2T3 and GLIS2 were 
identified in about 30% of children with non-DS AMKL324. The CBFA2T3-GLIS2 
fusion protein resulted from a chromosomal inversion of chromosome 16 where both 
CBFA2T3 and GLIS2 genes are localized on each arm of the chromosome 16 in 
proximity to the telomeres, in 16q24.3 and 16p13.3, respectively. CBFA2T3 (also 
known as MTG16) is a member of the ETO/CBFA2T1/MTG8 family containing three 
members related to the Drosophila melanogaster nervy gene, initially identified as a 
fusion partner with RUNX1 in t(16;21)(q24;q22) translocation of therapy-related AML 
and more recently, implicated in the maintenance of HSC quiescence. GLIS2 (GLI-
similar 2) is a member of the GLI-similar (GLIS1-3) subfamily of Krüppel-like zinc 
finger transcription factors and is closely related to the GLI family of transcription 
factors mediating the transcriptional response  to the Hedgehog pathway activation and 
is not expressed in megakaryoblastic cells. One of the nervy homology regions (NHRs) 
of CBFA2T3, which includes a myeloid, nervy and Deaf-1 domain (MYND) class of 
zinc finger domain reported to interact with the N-CoR repressor complex is lost as a 
result of the fusion to GLIS2. However, all of the GLIS2 zinc finger domains are 
present in the fusion protein, resulting in high level expression of the C-terminal portion 
of the protein including its DNA binding domain. Interestingly, patients with the 
CBFA2T3- GLIS2 fusion present a clear expression signature clustering them apart 
from other non-DS AMKL. Although the CBFA2T3-GLIS2 fusion protein has recently 
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been described as a distinctive feature of pediatric non-DS AMKL, the fusion protein 
has also been found in pediatric cytogenetically normal (CN) AML and not restricted to 
AMKL. 
There is currently limited understanding of the molecular basis for non-DS 
AMKL which affects current treatment options. Non-DS AMKL patients have a poor 
prognosis279,307,308 with a reported survival of 14% to 34% and the majority of patients 
relapsing within 1 year though the patients who undergo allogeneic stem cell 
transplantation after entering remission have significantly improved survival287.   
 
1.3.3 Prevalence of AMKL in Singapore and Malaysia 
 
Malaysia-Singapore multicenter leukemia study for childhood acute leukemia 
(MaSpore 2006), organized by Associate Professor Allen Yeoh, Department of 
Paediatrics, National University of Singapore, demonstrated that the incidence of 
AMKL (M7 subtype according to the FAB classification) in Singapore and Malaysia is 
strikingly high (18 out of 71, 25.4%, p=0.0003, 2x2 χ2–test, yellow bar in Figure 4.2A) 
compared to those in the worldwide populations (4.1 - 9.8%, green, violet and blue bars 
in Figure 1.13A). Likewise, another study in Singapore and Malaysia also showed high 
frequency of AMKL (29 out of 164, 17.7%, p=0.006, 2x2 χ2–test orange bar in Figure 
1.13A). Asian average (Avg) is calculated based on 6 distinct studies in Japan, Korea, 
Hong Kong and Taiwan (n=555); American avg, two studies (n=969); European avg, 5 
studies in Netherlands, Germany, UK and Italy (n=2,814). 
In the above mentioned two Singapore related studies, the numbers of DS 
patients within AMKL are 4 out of 18 (22%) and 10 out of 29 (34%) respectively. None 
of DS patients are seen in subtypes other than AMKL. This strong correlation between 
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AMKL and DS suggests that AMKL diagnosis in the two Singapore-related cohorts 
seems correct. 
Because the risk of having a baby with DS rises above 1 in 250 at the 35th 
birthday for women, it has become the standard care to offer the screen for DS to all 
mothers 35 years and older. In Singapore, the prenatal screening test for DS is well 
conducted for almost all mothers 35 years and older, and the risk of having a DS baby is 
expected to be very low compared to other countries where the screening is not 
routinely performed. Nevertheless, the frequency of AMKL including DS-AMKL is 
being reported to be high (Figure 1.13A). This high incidence of AMKL despite the 
estimated low incidence for DS suggests that Singapore-Malaysia populations carry 
unknown risk factors for AMKL. 
 












M0(%) M1(%) M2(%) M3(%) M4(%) M5(%) M6(%) M7(%) Others (%) 
MASPORE AML 2006 8.5 0.0 22.5 14.1 12.7 9.9 0.0 25.4 7.1 
Singapore& Malaysia study 4.9 1.2 21.3 12.2 12.2 9.1 1.2 17.7 20.1 
Asian Avg 2.4 13.7 33.2 6.5 16.3 13.9 2.5 9.8 1.6 
American Avg 0.9 19.4 27.1 5.4 20.2 15.7 2.2 6.5 2.6 
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Figure 1.13: Frequency of acute myeloid leukemia subtype in Singapore-Malaysia 
and other countries.  
(A) Incidences of each AML subtype, FAB classification M1 to M7, are shown in 
percentage.  
(B) Frequencies of each AML subtype in indicated races, Chinese (n=82), Malaysian 
(n=54), Indian (n=8) and others (n=20) in ‘Singapore & Malaysia study’ are given.  
 
Prognosis of AMKL depends on cause. One third of cases is associated with a 
t(1;22)(p13;q13) mutation in children. These cases carry a poor prognosis. Another 
third of cases is found in Down syndrome. These cases have a reasonably fair 
prognosis. The last third of cases may be heterogeneous, and carry a poor prognosis. 
Therefore, 66-78% of Singapore cases are expected to be poor prognosis. The proposed 
study regarding the locally relevant disease with poor prognosis holds both scientific 
and clinical significance, in particular for Singapore citizen’s health and wellness.  
Interestingly, the Notch agonist that I have tested is a natural product found 
abundant in edible cruciferous vegetables such as broccoli. As several studies have 
shown the cancer preventive activity of dietary botanicals, regular consumption of food 
naturally high with PEITC such as broccoli may help repress the development of DS-
AMKL in infants who suffered from TAM.  
 Furthermore, results obtained in my study have shown the promising potential 
of Notch agonist as an anti-cancer agent, thus, Notch agonist could serve as a lead 







AML-M0 AML-M1 AML-M2 AML-M3 AML-M4 AML-M5 AML-M6 AML-M7 AML No 
data on 
FAB Chinese (%) Malay Total (%) Indian Total (%) Others Total (%) 
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1.4 Mouse models for AMKL 
 
An earlier study has shown that mice bearing the Gata-1.05 knockdown allele have a 
significantly shorter life span and displayed marked splenomegaly characterized by the 
abnormal accumulation of cells of the erythroid and megakaryocytic lineages325. These 
mice were found to elicit two distinct types of acute leukemia, an early-onset c-Kit-
positive nonlymphoid leukemia and a late-onset B-lymphocytic leukemia326. 
 There are many other strains which recapitulate trisomy 21 such as Tc1, Ts16, 
Ts65Dn, and Ts1Cje mouse. Among these trisomy mice listed above, three strains 
summarized in Table 1.7 below are well characterized. Ts65Dn mice demonstrated 
myeloproliferative disorder (MPD) with megakaryocyte hyperplasia which is 
reminiscent of TMD and DS-AMKL. Moreover, Runx1 was shown to contribute to this 
hematopoietic phenotype. However, Ts65Dn mice which are trisomic for 104 orthologs 
of human chromosome 21 genes did not develop leukemia327. 
 




Abbreviations: MPD, myeloproliferative disorder; MK, megakaryocyte. (Compiled 




Previous study has shown that the GATA-1 promoter-driven Runx1 Tg mice 
developed a transient modest increase of MK marker-positive myeloid cells but no 
spontaneous leukemia, these mice were then crossed with myeloid-leukemia prone 
BXH2 mice whereby the presence of an extra copy of Runx1 in these mice resulted in 
shortening of the latency of leukemia with increased frequency of megakaryoblastic 
leukemia114. This suggests that increased Runx1 dosage contributes to leukemia 
development and plays a role in the development of myelomegakaryoblastic leukemia. 
 
1.5 Retroviral insertional mutagenesis 
 
Retroviral insertional mutagenesis (RIM) is a powerful whole-genome screening 
technique which has been successfully utilized in transgenic or gene knockout mice to 
identify causative oncogenes and tumor suppressor genes (TSGs), including those 
involved in the development of hematopoietic neoplasms330-332. The use of different 
insertional mutagens has been successfully used to reveal new proto-oncogenes333-335, 
and more importantly, the method has recently been used to identify cooperative genes 
for certain oncogenic stimuli331,336.  
Integration of the retroviral double-stranded DNA copy of their RNA genome 
into the genome of the host cell appears to occur randomly, suggesting that retroviruses 
can act as agents of insertional mutagenesis. Oncogenic retroviruses have been 
classified in two groups, acute and slow transforming retroviruses. Acute transforming 
retroviruses induce the formation of polyclonal tumors by highly expressing virus-
eoncoded oncogenes with short latency about 2-3 weeks, while slow transforming 
retroviruses drive the formation of mono-or oligoclonal tumors by inserting into the 
host genome proximal (approximately 300 kb) upstream or downstream of oncogenes 
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or TSGs with long latency about 3-12 months333. Acute transforming retroviruses are 
replication-defective as their viral genes are replaced with oncogene sequences and 
these viruses require co-infection with a related “helper virus” that provides the viral 
structural proteins to make infectious particles. However, slow transforming 
retroviruses do not carry viral oncogenes and have the standard genome organization of 
retroviruses and their capacity to induce neoplasms is based on the ability of their 
provirus to integrate in the host DNA, and mutate or transcriptionally activate flanking 
cellular genes.  
Forward insertional mutagenesis genetic screens using slow transforming 
retroviruses such as Moloney murine leukemia virus (MoMuLV, a γ-retrovirus) is a 
valuable tool for the identification of novel genes involved in the pathogenesis of 
human cancers333,337. The rationale of these screens is infecting newborn mice at 
postnatal day 3 (where the immune system has yet to develop) with replication-
competent, lymphotropic MoMuLV338, consequently acquires a life-long latent status 
within the organism as the mice were unable to mount an effective immune response 
against the virus. During this latent period, millions of host cells such as hematopoietic 
cells are infected and numerous proviral random integrations across the genome of host 
cells. When such insertions result in deregulation of nearby genes either by activation of 
proto-oncogenes or disruption of TSGs, the targeted cell may acquire a selective growth 
advantage, promoting their clonal outgrowth, acquiring multiple mutations after 
successive rounds of mutagenesis, eventually leading to the development of leukemia or 
lymphoma (Figure 1.14).   
In order to perform cancer gene discovery by insertional mutagenesis, the 
requirements are : (1) the proper oncogenic agent that efficiently integrates in a random 
or semi-random fashion into the host genome and deregulates the genes surrounding the 
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insertion site; (2) an animal model that is permissive to tumor formation; (3) efficient 
technologies to perform retrieval of integration sites; (4) bioinformatics and statistical 
tools to map integrations onto the host genome and to identify sites that are enriched for 
insertions, and hence loci containing candidate cancer drivers335. 
 
1.5.1 Uncovering genetic interactions in cancer 
 
Leukemogenesis is a multistep molecular process that requires combinations of specific 
activated oncogenic mutations, inactivated TSGs, epigenetic alterations of gene 
expression and structural abnormalities of chromosomes331,339. The discovery of a 
number of genes involved in leukemogenesis and their functional significance through 
molecular analysis of human cancers potentially provides important information about 
the underlying mechanism of synergy between molecular pathways in leukemogenesis. 
But more importantly, such information could help to further dissect the cooperative 
genetic interaction of individual genetic alterations in leukemogenesis as well as to help 
improve or direct future therapeutic intervention strategies. In other words, a gene can 
be defined as a putative cooperating gene if it is more frequently targeted in mice with 
specific genetic background compared to wild-type (WT) under the same retroviral 
insertional stress. I have applied this RIM method on Gata-1 knockdown; Runx1 
transgenic mice model to identify genes cooperating with Gata-1-deficient and Runx1-
overexpressing status in leukemogenesis. 
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Figure 1.14: Schematic diagram showing the RIM strategy. 
To initiate MoMuLV-mediated insertional mutagenesis, newborn mice are infected with 
MoMuLV at postnatal day 3 by injection with a supernatant of virus-producing cells. 
The virus will infect host cells and induce mutations in multiple ways by integration of 
the retrovirus in the host genome (green box). Proviral insertions can induce 
overexpression of cellular genes through the enhancers (enhancer insertions) that are 
present in the viral LTRs or by promoter insertions, creating a viral-host gene fusion 
transcript. Truncating or inactivating mutations may be induced by viral insertion 
within a host gene. Cells can be re-infected by the virus and thus accumulate multiple 
mutations that induce tumorigenesis. Abbreviations: RIM, retroviral insertional 
mutagenesis; MoMuLV, Moloney murine leukemia virus; LTR, long terminal repeat. 








1.5.2 Mechanisms of deregulation of genes by retroviral insertions 
 
Insertional mutagenesis mediated by DNA-integrating viruses (provirus) or 
retrotransposons into the host genome and subsequent deregulation of genes in the 
neighborhood of the insertion site by several mechanisms, including activation of 
transcription of flanking oncogenes by viral long terminal repeats (LTRs), or, more 
rarely, inactivation of TSGs, through disruption of coding sequences337,341 (Figure 
1.14). The mutagenic effects of the retrovirus are clonally selected because of a 
resulting pre-malignant growth advantage conferred by the virus330. Usually, a single 
genomic integration is insufficient to promote tumorigenesis and multiple rounds of 
proviral insertions within the same genome are required in order for a cancer to 
develop335.  
The most frequent mechanism of gene activation by insertional mutagenesis is 
transcriptional enhancement that results in the upregulation of endogenous gene 
expression, which may be explained by the flexibility with respect to the proviral 
orientation as well as the distance between provirus and target gene333. Although 
enhancer insertions usually act in an orientation-independent manner, however, 
classically, enhancer insertions are located upstream of a mutated gene in the antisense 
orientation, or downstream in the sense orientation, especially for retroviruses. Gene 
expression can also be affected by enhancer insertions over large distances as regulatory 
elements may be distal to a gene and the activity of elements may be affected via 
chromatin loops342, and thus complicating the identification of the affected genes.  
The other mechanism of gene activation is by promoter insertion, which occur in 
such a way that the integration of provirus is in the sense orientation in or close to the 
proximal promoter region of an endogenous gene, thereby replacing the function of the 
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normal promoter with elements found within the insertional mutagen which results in 
transcription driven by the promoter of the insertional mutagen. Frequently, joining of 
the first vector-coded exon to those of the host gene induced by splice signals from the 
integrating vector can result in the translation of high levels of chimeric 
transcripts337,343.  
Apart from these modes of action, proviral insertion into a cellular gene can 
interfere with the splicing of genes into which they integrate using engineered or 
endogenous polyadenylation signal of the LTR that may elicit premature termination of 
gene transcription335. Truncation of transcripts due to the premature termination may 
result in an mRNA encoding an inactive or unstable protein. Alternatively, landing of a 
provirus within a gene may result in aberrant splicing which abrogates gene function. 
Even though inactivation of both copies of a classical TSG may be a rare event as 
compared to activation of oncogenes in insertional mutagenesis that use retroviruses, 
identification of candidate TSGs is still possible with increasing the numbers of 
insertions per screen in order to increase the frequency of detection.  
 
1.5.3 Methods for the retrieval and analysis of integrations 
1.5.3.1 Mapping retroviral integration sites 
 
The completion of the mouse genome project in 2002 allows for strikingly enhanced 
mapping of the retroviral integration sites (RIS) onto the genome. Identification of 
genes that contribute to neoplastic transformation is made possible by identifying viral 
insertions in individual tumors that occur at frequencies higher than expected by 
chance. Often more than 2 insertions inside or near different oncogenes and tumor 
suppressor genes can be found in one tumor, indicating that the tumors are either 
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monoclonal with several RIS or polyclonal. In polyclonal tumors, some of the clones 
share one or more initiating oncogenic insertions but they also have additional 
insertions that are not shared between clones. Therefore, consecutive insertions of the 
virus at different stages of the clonal expansion of the infected cell within the same 
genome are required in order for tumorigenesis to occur. A subset of the clonal 
insertions found in a single tumor probably mark genes that are responsible for tumor 
initiation and progression, whereas others are passenger insertions that are co-selected 
during clonal outgrowth of tumor cells. Most insertions were thought to be random and 
not causally related to the disease due to cancer cells typically harbor many sites of RIS. 
On the other hand, genes in loci that recurrently contain proviral insertions in individual 
tumors, referred to common integration sites (CIS), were believed to represent 
pathogenic signatures334,344. A CIS is defined as 2 RIS within 30 kilobases (kb), 3 RIS 
within 50 kb or 4 or more RIS within 100 kb. Identified candidate cancer genes would 
require further experimental validation.  
Genes influenced by proviral integration and responsible for tumorigenesis can 
be identified through inverse polymerase chain reaction (iPCR) using proviral DNA as 
a molecular tag332. This is followed by mapping of the genomic sequences flanking the 
provirus to the mouse genome using the publicly available UCSC                            
(University of California, Santa Cruz) Genome Bioinformatics database 
(http://genome.ucsc.edu/)114,345,346. Regions in the genome that are found to carry 
insertions in multiple independent tumors significantly more frequently than expected 
by chance are called common insertions sites (CISs).  The data from many RIS screens 





1.5.3.2 BLAST-like alignment tool (BLAT) 
 
BLAT is a very effective tool which allows for the identification of the chromosomal 
position and candidate genes at the loci, thus enabling the identification of multiple RIS 
in each tumor. The program is designed to rapidly scan for relatively short matches 
(hits) of 95% and greater similarity of length 40 bases or more, and extends these into 
high-scoring pairs. However, it may miss more divergent or shorter sequence 
alignments346. 
 
1.5.3.3 Retroviral tagged cancer gene database (RTCGD) and Mutapedia 
 
Data of various retroviral insertional mutagenesis screens are compiled in the publicly 
available RTCGD homepage (http://variation.osu.edu/rtcgd) and Mutapedia homepage 
(http://mutapedia.nki.nl) which allows the identification of published CIS genes and 
corresponding retroviral integration site sequences for any chromosome or mouse 
genomic region of interest. The programs also enable the comparison of CISs identified 
in different laboratories using different mouse models and identify the CIS genes that 
are the most promiscuous347. Finally, these databases make it possible to easily identify 








1.6 Next-generation sequencing  
 
The advent of next-generation sequencing (NGS) technologies has facilitated massively 
parallel, cost efficient sequencing of genomic fragments concurrently with high 
throughput repertoire sequencing in comparison to the traditional Sanger sequencing by 
capillary electrophoresis348,349. NGS has many useful applications, ranging from 
measuring gene expression levels, detecting both rare and common disease-causing 
variants as well in both coding and non-coding regions using various NGS methods 
such as whole-genome and exome sequencing, targeted DNA and RNA sequencing. 
NGS has now become an unbiased, accurate and comprehensive approach for the robust 
detection of cancer-related mutations350. NGS technology constitutes various strategies 
that rely on a combination of template preparation, sequencing, genome alignment and 
assembly methods351.   
In cases where a suspected disease or condition has been identified, targeted 
deep-sequencing is preferentially employed as a rapid and cost-effective alternative to 
whole-genome and whole-exome sequencing, which focus on detection of known and 
novel variants in selected sets of genes or genomic regions with high specificity and 
sensitivity, improve the depth of coverage, while taking into consideration of critical 
factor such as maintaining low DNA input especially in human disease research 
applications352-354. Counting corresponding deep-sequencing reads allows the 
quantitative assessment of the mutation burden in a given sample. Utility of deep-
sequencing is currently reasonable in a diagnostic setting, where multiple genes or 
mutational hotspot regions of established markers thereof are sequenced in a massively 
parallel way by incorporating molecular barcodes and thus allows the multiplexing of 
multiple parameters and patients per sequencing lane. The efficiency of deep 
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sequencing approach can also be exploited for pre-clinical drug development to query 
the validity of xenograft model used in cancer research by enabling the comparison of 
the mutational profile of matched xenograft and primary tumor samples to study 
potential targets and evaluate therapies in a physiological context353. 
Thus far, groundbreaking discoveries made using NSG approaches has led to the 
identification of novel mutations for many key hematological malignancies such as 
AML, myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), hairy-
cell leukemia (HCL), Waldenström's macroglobulinemia (WM) or multiple myeloma 
(MM)352. Additionally, targeted NGS mutation screening using amplicon deep-
sequencing has already been successfully applied to genetically characterize a variety of 
myeloid malignancies.  
 
1.6.1 Sample preparation and technical challenges for NGS applications 
 
The various commercially available NGS platforms vary substantially in terms of 
template preparations, sequencing as well as data analysis. Nevertheless, amplicon 
preparation is a labor intensive part of the entire NGS process348. I have employed 
SureSelectXT2 Target Enrichment Solutions (Agilent Technologies) in pre-capture 
indexing formats to prepare amplicon libraries for Illumina Multiplexed Sequencing 
(Figure 1.15). This capture method is based on probe hybridization to enrich sequencing 
libraries made from whole genome samples351,352. Hybridization capture approaches 
generally work well but can suffer from off-target capture and struggle to effectively 
capture sequences with high levels of repetition or low complexity. Also, the probes are 
based on reference sequence, and variations that substantially deviate from the 
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reference, as well as significant insertion or deletion mutations, are not always going to 
be identified.  
Sequencing of short amplicons also makes obtaining entire sequences possible 
in either single read or using a paired-end read design by adding adapters directly to the 
ends of the amplicons and sequenced to retain haplotype information351. However, it is 
often necessary to design longer amplicons for targeted deep-sequencing applications, 
whereby the PCR products or amplicons need to be fragmented using acoustic shearing, 
sonication or enzymatic digestion for sequencing. An issue associated with amplicon 
sequencing is the presence of chimeric amplicons generated during PCR by PCR-
mediated recombination which can be exacerbated in low complexity libraries and by 
overamplification.  
           
Figure 1.15: Schematic diagram of hybrid selection method. 
The genomic DNA sample (‘pond’) is sheared and hybridized with biotinylated RNA 
library baits (ultra long 120mer). Magnetic streptavidin beads are used to pull down the 
complex of capture oligos and genomic DNA fragments. Unbound fragments are 
removed by washing. Finally the enriched fragment pool is amplified and the enriched 
sample is ready for sequencing and aligned to the bait sequences. (Adapted from ref352). 
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Most of the NGS studies thus far have been designed to fulfill specific aims such 
as discovering mutations, identifying somatic mutational signatures, characterizing 
clonal evolution and advancing personalized medicine350,356. Determining somatic 
mutations that are most likely to contribute to the cancer phenotype has been the most 
common aim of cancer-related NGS studies. Mutations can affect key domains of 
cancer genes associated with cancer progression and resistance to therapy, and exist in 
restricted regions of the genome termed mutational hotspots. Somatic mutation calling 
has several sources of false positives and false negatives, including technical bias, 
sequencing error, alignment artifacts, normal DNA contaminated with cancer DNA, 
tumor heterogeneity, copy number variants (CNVs) and copy-neutral regions of loss of 
heterogeneity (cnLOH)356.   
During the standard library construction process, PCR introduces duplicate reads 
and strand bias along with guanine-cytosine (GC) bias can be compounded351. Also, 
currently available NGS technologies have higher raw base-calling error rates than 
Sanger sequencing357. Therefore, attempts to minimize false-positive calls include 
further filtering which can ameliorate PCR artifact bias, increasing the depth of 
coverage to achieve higher consensus accuracy and making variant calling criteria more 
stringent. Alignment tools could produce artifacts in regions of low mappability such as 
low copy or simple tandem repeats that may be remediable to some extent by filtering 
based on mapping quality.  
NSG is a very powerful tool in molecular biology and it has a great potential. 
However, the major challenge in NSG technologies will be to analyze and manage the 
massive amount of sequencing data generated, which is bigger by several orders of 
magnitude in comparison to microarray analysis358. In addition, many researchers face 
serious problems with the use of increasingly complex mathematical models and 
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statistical tools as well as complicated programs and databases dedicated to the analysis 
of biochemical pathways and ontologies as data analysis can be time-consuming and 
may require special knowledge of bioinformatics to garner accurate information from 
raw sequence data, consequently depending heavily on the assistance of bioinformatics 
specialists348. Therefore, the successful use of NGS technologies require not only the 
development of new robust techniques of data processing and analysis but also the 
development of new user-friendly bioinformatics tools and statistical methods for 
handling of the growing number of collected data.   
 
1.6.2 NGS studies on AMKL 
 
At present, the majority of major cancer types have been characterized by exome and 
transcriptome sequencing. Table 1.8 presents the key findings according to underlying 
mutations and their impact on prognosis in AMKL. Often, discovery cohorts were used 
then subsequently the findings were verified in larger series of independent patient 
cohorts.    
For example, the increasing use of NGS technologies applied to study cancer 
genomes is making a remarkable contribution to our knowledge of the molecular 
landscape of AMKL. Following the identification of GATA-1 mutations and trisomy 
21, this strategy has recently led to the discovery of various genes recurrently mutated 
in AMKL and revealed driver mutations that potentially trigger progression of 






Table 1.8: Mutations detected in previous NGS studies on AMKL. 
 
 
Abbreviations: DS, Down syndrome; AMKL, acute megakaryoblastic leukemia; TMD, 
transient myeloproliferative disorder; TAM, transient abnormal myelopoiesis.  











1.7 Aims of the project 
 
Children of Down syndrome (DS), the most common congenital disease, are at high 
risk of developing a specific subtype of acute myeloid leukemia, acute 
megakaryoblastic leukemia (AMKL). According to Malaysia-Singapore multicenter 
leukemia studies for childhood acute leukemia, the prevalence of AMKL in Singapore 
and Malaysia is strikingly high as compared to those in the worldwide populations, and 
its prognosis is unfavorable. Despite such widespread and local relevance, the 
mechanistic basis for AMKL remains elusive. 
The first aim of my project is to comprehensively identify genetic changes 
associated with AMKL. To this end, an AMKL mouse model was developed employing 
RIM on the genetically engineered mouse with alterations in Gata-1 and Runx1 genes. 
RIM allows for the easy identification of disease genes by simple PCR-based technique. 
The second aim of my project is to validate whether the genetic alterations 
detected in the RIM mouse model are also affected in human AMKL samples. For this, 
I employ targeted deep sequencing strategy in 40 AMKL patient samples and 7 AMKL 
cell lines.  
Based on the information of mutations newly unveiled in the above mentioned 
mouse and human AMKL studies, the third aim of my project is to develop novel and 








CHAPTER 2: MATERIALS AND METHODS 
 
Mice. Runx1 transgenic (Tg) mouse that over-expresses mouse Runx1 in 
hematopoietic cells under the control of the hematopoietic regulatory domain (HRD) of 
GATA-1 promoter was generated as previously described361 and maintained on the 
C57/BL6 background. Gata-1 knockdown mouse, Gata-1.05 with BALB/c background, 
is rendered genetically defective in the synthesis of mouse Gata-1 mRNAs from the 
erythroid-specific promoter at approximately 5% of the level present in wild-type 
embryos362. All mice were kept in specific pathogen free conditions and all animal 
procedures were performed according to the National University of Singapore 
Institutional Animal Care and Use Committee (IACUC).  
 
Genotyping. Genomic DNA was extracted from mouse tails using Direct PCR Lysis 
Reagents (Viagen Biotech, Los Angeles, CA), while genomic DNA from other tissues 
were extracted using the phenol/chloroform method. Genomic DNA samples were then 
used for genotyping by PCR. Reactions (20 μl) were performed with the following 
primers (0.1 μM), 0.5 mM dNTPs, 2.5 mM MgCl2, 2.5 U GoFlexi Taq polymerase and 
100 μg to 200 μg DNA. DNA was denatured at 95°C for 5 minutes then amplified by 
30 cycles at 95°C for 45 seconds, 60°C for 50 seconds, and 72°C for 45 seconds. The 
amplified PCR products are detected visually after separation by electrophoresis on a 
2% GelRed-stained agarose gel. Sequences of the primers used were as follows: 
endogenous Runx1 transcript (expected size, 253 bp),                                                           
5’-AGCATGGTGGAGGTACTAGC-3’ and 5’-GGTCGTTGAATCTCGCTACC-3’; 
transgene-derived Runx1 transcript, 5’-GGTGGCTGAATCCTCTGCAT-3’ and the 
reverse primer used for the endogenous Runx1 transcript primer set;                   
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erythroid-specific Gata-1 transcript (expected size, 483 bp),                                                     
5’-TAAGGTGGCTGAATCCTCTGCATC-3’ and                                                               
5’-CCGTCTTCAAGGTGTCCAAGAACGT-3’; testis-specific Gata-1 (expected size, 
529 bp), 5’-CGTGAAGCGAGACCATCGTC-3’ and the reverse primer used for the 
erythroid-specific Gata-1 transcript primer set; neomycin phosphotransferase           
(expected size, 339 bp), 5’-AAGTATCCATCATGGCTGATG-3’ and                         
5’-TAGCCAACGCTATGTCCTGATA-3’. Neo gene primers were used for detecting 
the Gata-1.05 allele, because the mutation was generated by inserting a Neo gene 
cassette into the 58 flanking region of the GATA-1 locus. 
 
Analysis of PB cells.   PB was collected by retro-orbital bleeding and CBC were 
performed using an automated hemocytometer (Reichert Scientific Instruments, 
Buffalo, NY, USA). Mice were analyzed for PB morphology, after May-Grunwald-
Giemsa staining of PB smears, upon demonstration of phenotype. 
 
Isolation of BM cells.   BM cells were flushed from the long bones (tibias and femurs) 
with minimum essential medium alpha medium (α-MEM) (Invitrogen Corporation, 
Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum 
(Biowest, France). Cells were filtered through nylon filter (35 μm) to obtain a single-
cell suspension. 
 
Cytospin preparation.    BM cells were obtained from mice upon demonstration of 
phenotype. 5-10 x 104 cells per well were cytospun using a cytocentrifuge (Cytospin4, 




May-Grunwald-Giemsa staining. The slides were first stained with May-Grunwald 
stain solution [May-Grunwald solution (Merck KGaA, Darmstadt, Germany) : Methyl 
Alcohol = 1:3] for 5 minutes. After draining off the solution, the slides were stained 
with Giemsa stain solution [Giemsa solution (Merck KGaA, Darmstadt, Germany) : 
phosphate buffer (pH6.4, KH2PO4 6.63 g, Na2HPO4 2.56 g / 1000 ml) = 1:20] for 20 
minutes at room temperature. Slides were then washed with running water and air-
dried.  
 
Flow cytometric analysis and cell sorting. BM, spleen or liver single-cell suspensions 
were pre-incubated with normal mouse serum (EMD Millipore Corporation, Billerica, 
MA, USA) for 15 minutes on ice before staining to block nonspecific binding. Samples 
were centrifuged and pellets were resuspended in FACS buffer (PBS, 1% bovine 
growth serum and 0.01% NaN3) and the fluorochrome-conjugated antibody reaction 
was carried out for 20 minutes on ice. The antibodies used in this study were FITC-
conjugated antibodies (anti-Gr-1, anti-CD41, anti-CD71, anti-CD25 and anti-B220) as 
well as PE-conjugated antibodies (anti-cKit, anti-CD61, anti-Ter119, anti-CD44 and 
anti-CD3). All monoclonal antibodies were purchased from BD Pharmingen (San 
Diego, CA, USA). After washing, cells were resuspended in FACS buffer and 0.5 
μg/ml of Hoechst 33258, pentahydrate (Invitrogen Corporation, Carlsbad, CA, USA) 
were added to exclude dead cells, flow cytometric analysis was performed using BD 
LSRII instrument (BD Biosciences) and analyzed using the FlowJo software (Tree Star 





RIM. Runx1 Tg and Gata-1.05 mice were mated and all F1 progenies were inoculated 
intraperitoneally with Moloney murine leukemia virus (MoMuLV) 3 days after birth 
and monitored by examining their health condition and CBC analysis. Mice were 
carefully observed daily upon observation of symptoms and/or when WBC counts 
increased beyond 20 x 103/μl. Moribund mice were then sacrificed and subjected to 
necropsy. Abnormalities in hematopoietic tissues were recorded as follows: 
enlargement of the spleen, liver and thymus, and swelling of lymph nodes. 
Leukemic/lymphoma cells from PB, BM, spleen and thymus were subjected to May-
Grunwald-Giemsa staining. Immunophenotype analyses were carried out by flow 
cytometric analysis to check for the presence of cell surface markers for immature cells, 
myeloid cells, T-cells and B-cells in the BM or thymus of leukemic or lymphoma mice, 
respectively. 
 
Identification of RIS by iPCR.     For all viable tumor samples, 5 μg of genomic DNA 
extracted from mouse leukemic/lymphoma cells from the spleen or thymus was 
digested by BstYI and self circularized overnight by T4 DNA ligase (New England 
Biolabs, Inc., MA, USA) at 16°C. Then 5’ and 3’ integration flanking fragments were 
amplified individually by iPCR. The first PCRs were performed using AccuPrime Taq 
(Invitrogen Life Technologies, Carlsbad, CA, USA) employing an initial preheating 
step at 95°C for 5 minutes followed by 30 cycles of 95°C for 1 minute, 60°C for 1 
minute and 68°C for 3 minutes. The second PCRs were performed by GoFlexi Taq 
(Promega, Madison, WI, USA) employing an initial preheating step at 95°C for 5 
minutes followed by 35 cycles of 95°C for 1 minute, 55°C for 1 minute and 68°C for 2 
minutes. The amplified PCR products were cloned by the TA cloning method using the 
plasmid pDrive cloning vector (Qiagen GmBH, Hilden, Germany) and subjected to 
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cycle sequencing (1st BASE, Singapore) using the M13-forward and M13-reverse 
primer. The position mapping of the RIS on the mouse chromosome was performed by 
BLAT searching of the UCSC Genome Bioinformatics database 
(http://genome.ucsc.edu). The definition of a CIS was the same in the RTCGD 
(http://variation.osu.edu/rtcgd/); each window size is 100, 50, or 30 kb for CIS with 4 
(or more), 3, or 2 insertions, respectively, in each model. 
 
Genomic DNA samples. AMKL patient samples used for this project were derived 
from samples collected specifically for the childhood leukemia tissue bank amongst 
hospitals in Malaysia and Singapore, which was established by Associate Professor 
Allen Yeoh. All samples for this project were taken with written informed consent and 
all the data were anonymized and only information on gender and ethnicity of the 
patients were taken. Genomic DNA was isolated from bone marrow using the standard 
phenol-chloroform extraction method.  
 
Whole genome amplification.   Whole genome amplification (WGA) was performed 
using the commercially available REPLI-g Mini Kit (Qiagen GmBH, Hilden, Germany) 
following the manufacturer’s protocol. The starting amount of genomic DNA input into 
the WGA reaction was more than 10 ng in all cases. The REPLI-g method is based on 
Multiple Displacement Amplification (MDA) and includes denaturation of DNA and 
isothermal amplification. DNA was denatured by adding 5 μl of denaturation buffer D1 
to 5 μl of template DNA and the sample was incubated at room temperature for 3 
minutes. Denaturation was stopped by adding 10 μl of neutralization buffer N1. 
Preparation of the REPLI-g master mix were performed on ice by adding 29 μl of 
REPLI-g mini reaction buffer and mixed by vortexing and centrifuged briefly before the 
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addition of 1 μl of REPLI-g mini DNA polymerase. Then the 30 μl of REPLI-g master 
mix were added to the sample, and amplification was performed 30°C for 16 hours. 
REPLI-g mini DNA polymerase was inactivated by heating at 65°C for 3 minutes. 
Concentrations of amplified DNA were measured with Qubit dsDNA BR kit, according 
to the protocol supplied by the manufacturer (Invitrogen Corporation, Carlsbad, CA, 
USA). 
  
DNA shearing.    The first step in Agilent SureSelectXT2 preparation is DNA 
fragmentation, which was performed on a Covaris S220 system (Covaris, Inc., Woburn, 
MA, USA). Shearing of 1 μg of genomic DNA was carried out in 50 μl of 1x TE buffer 
using the following instrument parameters: duty cycle 10%, intensity 5, cycles per burst 
200, time 6 cycles per 60 seconds. The resulting size distribution and concentration 
were checked using the Agilent 2100 BioAnalyserDNA1000 assay (Agilent 
Technologies, Santa Clara, CA, USA).  
 
Agilent SureSelectXT2 library preparation for pre-capture sample processing. 
Libraries were prepared starting from 1 μg of original and REPLI-g amplified DNA 
according to the sample preparation guidelines of the Agilent SureSelectXT2 Target 
Enrichment System for Illumina Multiplexed Sequencing Protocol. The protocol 
comprises standard steps for Illumina DNA library preparation: end-repair of 
fragmented DNA, A-tailing, adapter ligation and amplification. Purifications between 
steps were carried out with Agencourt AMPURE XP beads (Beckman Coulter, Inc.). 
The libraries’ yield, estimated with Qubit dsDNA HS kit (Invitrogen Corporation, 




Cell lines and culture conditions. AMKL cell lines (CMK, CMK-11-5, CMK-86, 
M-07e, MG-S, and MEG-01) and T-ALL cell lines (KOPT-K1 and Jurkat) were 
cultured in RPMI 1640 medium, containing 10% fetal bovine serum (Biowest, France), 
or 20% fetal bovine serum (Biowest, France) for MOLM-16, together with 2 mM L-
glutamine, and 100 units/mL penicillin and streptomycin at 37⁰C in a humidified 
atmosphere with 5% CO2 and AMKL cell line, M-07e, was cultured in addition of 
human interleukin-3 (IL-3). AMKL cell line, UT-7 was cultured in basic growth 
medium (BGM) consisting of alpha-minimum essential medium (α-MEM) (Invitrogen 
Corporation, Carlsbad, CA, USA) containing 20% fetal bovine serum, 2 mM L-
glutamine, and 100 units/mL penicillin and streptomycin at 37⁰C in a humidified 
atmosphere with 5% CO2. 
 
Measurement of cell viability. AMKL and/or T-ALL cells were seeded at a density of 
2 x 105 cells/ml in 100 μl volume per well in a 96-well plate. Leukemic cells were 
treated with JAK inhibitor 1, γ-secretase inhibitor (DAPT) or phenethyl isothiocyanate 
(PEITC), or combination therapy. The proliferation of leukemic cells following 144 
hours of treatment was assessed using Colorimetric CellTiter 96 Aqueous One Solution 
Cell Proliferation Assay (MTS assay, Promega, Madison, Wisconsin, USA). The 
absorbance of each well was recorded at 490 nm using Tecan Infinite M200 plate reader 
(Tecan, San Jose, California, USA). Each treatment was carried out in triplicate and the 
percentage of viable cells was reported as the mean of optical density of the treated 
wells divided by the mean of optical density of dimethylsulfoxide (DMSO) control 
wells after normalization to the background absorbance from wells without cells. The 
median inhibitory concentration (IC50) was determined by MTS assay and calculated by 
CalcuSyn software (Biosoft, Cambridge, UK). 
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Assessment of apoptosis of AMKL cells. For flow cytometric evaluation of 
apoptosis in AMKL cell lines, the cells (CMK, MG-S and MEG-01) were grown in 6-
well plates and then treated with γ-secretase inhibitor (DAPT) or PEITC at the desired 
concentrations. After exposure to drugs for 8 hours, 1 x 106 cells (CMK, MG-S and 
MEG-01) were washed with phosphate-buffered saline (PBS) and resuspended in 
binding buffer (10 mM HEPES (pH7.4), 140 mM NaCl, 2.5 mM CaCl2). Cells were 
incubated with 1.5 µl of Annexin V-FITC (BD PharMingen) and 1 µl of propidium 
iodide (PI) for 15 minutes at room temperature in the dark, followed by addition of 400 
µl of binding buffer. Ten thousand events were acquired on a BD LSRII flow cytometer 
(Franklin Lakes, NJ, USA).  Results were expressed as percentage of specific apoptosis, 
according to the following formula: % specific apoptosis = [(% of apoptotic treated 
cells - % of apoptotic control cells) x 100] / (100 - % of apoptotic control cells).  
 
Caspase 3/7 activity assay. Following treatments cells were subjected to Caspase 3/7 
activities measurement with Caspase-Glo assay kit (Promega, Madison USA). Briefly, 
the white, opaque 96-well plates containing cells were removed from the incubator and 
allowed to equilibrate to room temperature for 30 minutes. 100 μl of Caspase-Glo 
reagent was added to each well, the content of well was gently mixed with a plate 
shaker at 300–500 rpm for 30 seconds. The plate was then incubated at room 
temperature for 30 minutes. The luciferase substrate derivative is specifically cleaved 
by active caspase-3/7 resulting in the conversion of the substrate into a luminescent 
signal (RLU). The luminescence of each sample was measured in a Tecan Infinite 
M200 plate-reading luminometer (Tecan, San Jose, California, USA) with parameters 
of 1 minute lag time and 0.5 second/well read time. The experiments were performed in 
triplicate and repeated on two separately-initiated cultures. 
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Neon transfection. AMKL cells (CMK, MG-S and MEG-01) were plated at 2 x 106 
cells per well in 6-well plate and transiently transfected with 1.5 μg of Hes1 promoter 
firefly luciferase reporter construct or 0.5 μg of pMax-GFP control plasmid and 1ng of 
pRL-SV40 vector containing Renilla luciferase plasmid (Promega Corp., Madison, WI, 
USA) using Neon transfection system (Invitrogen, Life Technologies, Carlsbad, CA, 
USA).  
 
Luciferase reporter assay. Luciferase activities were determined 24 hours after 
transfection using a dual luciferase reporter assay system (Promega Corp., Madison, 
WI, USA). All reagents were prepared as described by the manufacturer. The 5× 
passive lysis buffer was supplied by the manufacturer and used for cell lysis. Briefly, 
transfected cells were grown in the appropriate medium for 16 hours and treated with 
either γ-secretase inhibitor (DAPT) and/or PEITC for another 8 hours, and then the cells 
was removed directly from culture and transferred to 100 μl of 1× passive lysis buffer. 
After allowing lysis for 10 to 15 seconds, a 10-μl aliquot was used for luminescence 
measurements with a Tecan Infinite M200 plate reader (Tecan, San Jose, California, 
USA). The following steps were used for luminescence measurements: 100 μl of the 
firefly luciferase reagent (LARII) was added to the test sample, with a 10-s 
equilibration time and measurement of luminescence with a 10-seconds integration 
time, followed by addition of 100 μl of the Renilla luciferase reagent and firefly 
quenching (Stop & Glo), 10-seconds equilibration time, and measurement of 
luminescence with a 10-seconds integration time. Results were represented as the ratio 




Quantitative reverse transcription-PCR (qRT-PCR). AMKL cells (CMK, MG-S and 
MEG-01) were seeded at a density of 5 x 105 cells/ml in 6-well plates and then treated 
with γ-secretase inhibitor (DAPT) and/or PEITC at the desired concentrations and cells 
were then incubated for 8 hours at 37⁰C. RNA samples were isolated using QIAzol 
Lysis Reagent and RNeasy Mini kit (Qiagen GmBH, Hilden, Germany). Total RNA 
was reversed transcribed to cDNA using iScript Reverse Trasncriptase Supermix for 
RT-qPCR according to the manufacturer’s protocol (Bio-Rad, Hemel Hempstead, UK). 
The resulting cDNA was used as the substrate to measure relative expression levels by 
qRT-PCR with primers specific for human HEY1 and GAPDH for normalization: 
HEY1 forward  5’-AACTGTTGGTGGCCTGAATC-3’ and HEY1 reverse                       
5’-GCTGGTAAATGCAGGCGTAT-3’;  _________ GAPDH _________forward            
5’-GGACCTGACCTGCCGTCTAGAA-3’ and GAPDH reverse                                   
5’-GGTGTCGCTGTTGAAGTCAGAG-3’.  Duplicate reactions were prepared and 
qPCR was performed using a Rotor-Gene 6000 (Qiagen GmBH, Hilden, Germany) 
instrument with the following run specifications: Hot start primer activation for 10 
minutes at 95⁰C, followed by 45 cycles of duplex melting for 10 seconds at 94⁰C and 
annealing for 45 seconds at 55⁰C. Threshold-cycle (Ct) values were automatically 
calculated for each replicate and used to determine the relative expression of the gene of 
interest relative to reference gene for both treated and control samples by the 2-ΔΔCt 








Table 2.1: Primer sequences used for mutation screening. 




GATA1-Ex2 F AGAGGAGCAGGTGAAAGGATGT 
382 GATA1-Ex2 R TGACCTAGCCAAGGATCTCCAT 
NOTCH1 e22 FW TGGGGTTTTCCCTTCCCCTA 755 
NOTCH1 e22 RV GGTTTCGTCAGTGGCCCAAG 
NOTCH2 e1 FW TTCGTTGCACACCCGAGAAA 658 
NOTCH2 e1 RV CGGAACCTGAAGGGCAAAAC 
NOTCH2 e1 FW2 CTGGAGAAGGATGCGGACG 839 
NOTCH2 e1 RV2 AACCTGAAGGGCAAAACTGC 
NOTCH2 e1 FW3 CTTTGAAGCAGGAGGAGGGG 273 
NOTCH2 e1 RV3 CACACAGAGAAGGACCGAGG 
NOTCH2 e3 FW AGGTGGTCCTTGTAGGTCTGT 583 
NOTCH2 e3 RV TCTCTTTCTCTGCCCCCTGA 
NOTCH2 e4 FW CCACCCACTGAGTCCTTGTG 714 
NOTCH2 e4 RV GGGCCCATAAAACTCCTCCC 
NOTCH2 e7 FW GCTCCACTTTCCTGTCTCCG 713 
NOTCH2 e7 RV GCTATTGCAGTTTCTGCCCA 
NOTCH2 e17 FW AACATGGGTGTGGAGAAGCC 690 
NOTCH2 e17 RV CCAATGTCAGGCGTGAAAGG 
NOTCH2 e17 FW2 GGGTGTGGAGAAGCCAAGAA 684 
NOTCH2 e17 RV2 CAATGTCAGGCGTGAAAGGC 
NOTCH2 e26 FW TGGGCCACAGAAAATGGGTAG 732 
NOTCH2 e26 RV GAGGCAACTCTGGCAAAAGG 
NOTCH2 e29 FW AGAGCGTGGGTGCATCTATT 640 
NOTCH2 e29 RV TGACTTGACTACTGCCAGCAT 
NOTCH2 e34 FW TGTGCGCCTTCTGGATGAAT 720 
NOTCH2 e34 RV CGAGGGGTGGTTATGTGCTT 
NOTCH2 e10 FW AGAGAGAAGGTTTCTGTTGCCT 763 
NOTCH2 e10 RV GCTGAGAAGCCCCAGTGAA 
NOTCH3 e28 FW TTGCTGCTGGTCATTCTCGT 
710 
NOTCH3 e28 RV CACCTCCAGGAAGAGTGCAG 
NOTCH3 e30 FW CCCTGTGCCCTAGGAGTAGT 731 











NOTCH4 e7 FW CTCTTTCTCCTGCCTCTGCC 593 
NOTCH4 e7 RV GACTGTCAGGGAAGGTGTGG 
NOTCH4 e7 FW2 GAGAGCCTCACCCCCTCTTA 378 
NOTCH4 e7 RV2 GGGACCAAACTCATGGGGAC 
NOTCH4 e16 FW CACCTTCTCCTGCCTCTGTG 771 
NOTCH4 e16 RV TTTGCTCTCCAGTCAGTGCC 
NOTCH4 e29 FW TGAGATGCGGTGGAAGTACG 792 
NOTCH4 e29 RV CCCAGTGGTTACGTTGGTGA 
NOTCH4 e29 FW2 CTGGGGTAACAACCTCCCAC 284 
NOTCH4 e29 RV2 CCGATATCAGGGAAGGCCAC 
MAML1 e2 FW GCAAGGCTCCATCTCAAAAC 
792 MAML1 e2 RV TGAGGTCTGGCATGAGGTTG 
MAML1 e3 FW GCCCTGTGGGATGGTTGTTA 
507 MAML1 e3 RV ACTCTAACAACAGGCACGCA 
MAML1 e4 FW CACAGGAGCCCATTTGTGAG 
748 MAML1 e4 RV GCCTATGAAGTTCCCTGGCA 
MAML2 e1 FW TATGAACGAGGTAGGGCCGA 
730 MAML2 e1 RV CTGAAAAATGGCTTGGGGGC 
MAML2 e2 FW TTTGTGCTCTCTCTGTGCCA 
525 MAML2 e2 RV CAGGGTCGTCTCCGTACCTA 
MAML2 e2 FW2 AGCCAGAGGAGCACACCTAG 
633 MAML2 e2 RV2 AGGCTTGGTGTTGCCCTGAC 
MAML2 e2 FW3 CAGATCAAGCGAACCAGCAG 
619 MAML2 e2 RV3 TAGATGCCCTCAACGAACCA 
MAML2 e5 FW GCCACCTACCTTAGGGCCAA 
646 MAML2 e5 RV ATCACTGTTTAGGGCAGGGC 
APH1A-1F GCTGCTGTCTCTGTCCTTCTA 
740 APH1A-1R GTCTCTCAGGGAAGGCCAAT 
NCSTN-1F AAAGAGACCTCCTGCTTCCCAT 
499 NCSTN-1R AGAGCTAGGGAGCAGTGGAA 
NCSTN-2F#2 CAGGGGATTGGGATGGAGAG 












774 SPEN-1R ATAGGGGTGCAGTCGGTACT 
SPEN-2F GCGATCCAAGCATCCCCATA 
730 SPEN-2R ACATTCACTGGCCCCGTAAG 
SPEN-3F CTCCTTACCTGGAACCCCGA 
426 SPEN-3R TTCTGCTTGTGCCCTCTGAA 
SPEN-4F CAGTTGCAAAGACAAAGACA 
664 SPEN-4R ACTATGCTGAAACCATTCCCA 
SPEN-5F GTCCGACATGGTTCCTTCCA 
467 SPEN-5R TCTCGCTCACGTAGCTTGTC 
SPEN-6F TCGCCAAGGTCCCAGAAAAC 
404 SPEN-6R ACCACCCCAGATTCCCTCTC 
SPEN-7F AGCCCCATCAGCACTAGAGA 
572 SPEN-7R CGGGCTTCTCCACGATACTC 
SYNE1-1F AATGCAGTCTTGAGACACAGTC 
428 SYNE1-1R ATGTTCTTCACAAAAGAGCCAC 
SYNE1-2F TTACGCTGCAGAGAACTGGG 
437 SYNE1-2R TTGTCGCTTCAGCCTGTGAT 
SYNE1-3F CTCAGTGGTTCCAGTGGCTG 
556 SYNE1-3R TGCCCTAGTATCACCTGTATTTATG 
SYNE1-4F CCCTTTGGACCCAGCAATGT 
507 SYNE1-4R TGGGACCGAACAGCATTTGA 
SYNE1-5F GGGCCCACCTTTCTGTACTT 
510 SYNE1-5R ACAGCACCTAGTCCTCAAAC 
SYNE1-6F ACCCTGACTTTCTCCTGCCT 
479 SYNE1-6R AGGACCTAAGTGGCGTGAAT 
SYNE1-7F CCTCTGCCATAGACTGTAGTG 
720 SYNE1-7R AAGAGACAAGTGGCCGTGAC 
SYNE1-8F GCACTGTGGTGACCTTCGTA 













JAK1 exon 5 FW GGTTTGCCAGGAGCTACAGT 
560 JAK1 exon 5 RV AATGTGGCAGAGGAAGGTGA 
JAK1 exon 14 FW CCCTGTTTGCAGTGTCCTGA 661 
JAK1 exon 14 RV GCTGAGTGTGAGGAGCTGTT 
JAK1 exon 22 FW TAATGAAGGGGCGAAGCTGG 635 
JAK1 exon 22 RV ACGTATTGCCGAGAACCCAA 
JAK2 exon 3 FW TGCTGTTGGAAAAATGGTGCT 774 
JAK2 exon 3 RV ACAAAACGCTGCACAAACCA 
JAK2 exon 9 FW ACCTTTAGGATGGATTTTGCCA 519 
JAK2 exon 9 RV TCCTCTAATTCTGCAACCACTGT 
JAK3 exon 14 FW CAGACAGGGCTCAACACCTT 527 
JAK3 exon 14 RV ACACGCCCTGACATCCAAG 
JAK3 exon 15 FW GGTGTTTGAGAAGGGGAGGG 670 
JAK3 exon 15 RV CCCCAACCCAATAGACCCAC 
JAK3 exon 17 FW GGCATTTTCCTGTGTCTGGC 783 
JAK3 exon 17 RV CCTCCAACCTCACCAGACAC 
JAK3 exon 20 FW GTGTCATTGTTGCGGTTCCC 712 
JAK3 exon 20 RV CCACCAGAAAATGGGGCTCT 
MPL exon 2 FW ACACAGTGGCGGAGAAGATG 644 
MPL exon 2 RV CCCATGCCCAACTTCTGTCT 
MPL exon 4  FW GCCCCAGAGATCCCAAGAAC 618 
MPL exon 4  RV GAGTCCTGAGATGAGGCAGC 
MPL exon 7 FW GGGAAGAGGCCAGACAACAA 600 
MPL exon 7 RV TACAGGGATGTCAGCAGGGA 
MPL exon 10 FW CACGCTTCTTTGCTCAGGTG 729 















PIAS1 SeqEx2F GTGAGCTGGCCTTTATTTGC 313 
PIAS1 SeqEx2R CAGGCGTCATGATTTTCTGTG 
PIAS1 SeqEx14F CAACACCTCCTTGCTTGCCG 333 
PIAS1 SeqEx14R TTCATTCGATCTGGGGTGGGG 
PIAS2 SeqEx2F GGCGGATTTCGAAGAGTTGAGG 436 
PIAS2 SeqEx2R CACATCAGGATGGACAGGAGGA 
PIAS3 SeqEx5F GAGGGCTTCAGGCATCTATGAC 314 
PIAS3 SeqEx5R CCTACTATGTGCCACGCACTG 
PIAS3 SeqEx7F GGAACCATCCAGTGTCCTG 294 
PIAS3 SeqEx7R GCCAGGAAGACTTGAATCCAG 
PIAS3 SeqEx11F CCTGTTCCCCAGCTAAGCT 296 
PIAS3 SeqEx11R GCAATCCTGACTTCTTCCCC 
PIAS4 SeqEx2F CAGATGCTCCTGGGTTTCGTG 405 
PIAS4 SeqEx2R CCACTCACCTAATTCGGTGGG 
 
 
Statistical Analysis. Differences between samples were evaluated by unpaired two-
tailed student‘s t-test. All values are expressed as means ± S.E.M. Bioinformatics 
analysis on raw sequence data from targeted deep sequencing was performed by 













CHAPTER 3: RESULTS 
 
3.1 Runx1 Tg/Gata-1.05 compound mice develop megakaryoblastic 
leukemia 
 
Several lines of evidence have demonstrated that constitutional trisomy 21 and acquired 
somatic N-terminal truncating GATA-1 mutations together may not be sufficient to 
cause AMKL in DS and additional genetic alterations are needed to transform 
TAM/TMD into overt AMKL. Therefore, an AMKL mouse model employing RIM 
strategy on the genetically engineered mouse was generated to identify potential genes 
cooperating with Gata-1-knockdown and Runx1-overexpressing status in 
leukemogenesis. Runx1 transgenic mouse (Runx1 Tg) which overexpresses Runx1 in 
hematopoietic cells under the control of hematopoietic cell specific promoter element of 
GATA-1 gene was generated previously to, at least in part, recapitulate trisomy 21. In 
addition, GATA-1 mutation was introduced by employing Gata-1 knockdown mouse 
(Gata-1.05). These Runx1 Tg and Gata-1.05 mice were mated to generate wild-type 
(WT), Gata-1.05, Runx1 Tg, and compound mice (Runx1 Tg/Gata-1.05). All F1 
progenies were injected with MoMuLV and when these mice became moribund, they 
were sacrificed and necropsy was carried out. Intriguingly, leukemia cells from 6 out of 
the 16 (37.5%) Runx1 Tg/ Gata-1.05 mice were positive for megakaryoblast markers (c-
Kit+ CD41+ CD61+) (Figure 3.1A), and majority of them exhibited cytoplasmic blebs, 
one of the typical morphological feature of megakaryoblastic leukemia (Figure 3.1B). 
Leukemia cases showed elevated WBC counts and hepatosplenomegaly with normal 
thymus and lymph nodes, while lymphoma cases showed normal or mildly elevated 
WBC counts and enlarged thymus or lymph nodes. Based on the combination of WBC 
 87 
 
counts, necropsy, immunophenotype and morphological analyses, the diseased mice 
were classified into the following 5 groups (Table 3.1): (1) megakaryoblastic leukemia, 
(2) myeloid leukemia, (3) biphenotypic (myeloid and T-cell) leukemia, (4) T-cell 
leukemia, and (5) T-cell lymphoma. AMKL-like leukemias developed in 2 of 9 (22%) 
Runx1 Tg mice, but not in any of 11 Gata-1.05 as well as 9 WT mice.   
 
Table 3.1: Frequency of different types of cancers in MoMuLV-inoculated mice. 
  
*Cancer classification was conducted based on combination of leukocyte counts, 
necropsy, immunophenotype and morphological analyses. The details of these analyses 
are described elsewhere. Abbreviations: WT, wild-type littermate control; Gata-1.05, 
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Figure 3.1: Immunophenotype and morphology of megakaryoblastic leukemic 
cells from a Runx1 Tg/Gata-1.05 compound mouse #1472. 
(A) Representative flow cytometry analysis of the leukemic cells from the 
compound mouse. Percentages of indicated antigen-positive or –negative cells 
are shown in the profiles. The top-left profile without any antibodies serves as a 
negative control.  
(B) Representative morphology (May-Giemsa staining) of the leukemic cells, some 






3.2 Cooperation of genetic hits with Gata-1-knockdown and Runx1-
overexpressing status in leukemogenesis 
 
To identify the RIS in the compound mice (Runx1 Tg/Gata-1.05), as well as the Runx1 
Tg, Gata-1.05 and WT mice, genomic DNA were extracted from the 
leukemia/lymphoma cells in tumor containing organs and subjected to the inverse PCR 
method. An individual tumor (leukemia/lymphoma) induced by MoMuLV generally 
had 2 to 14 RIS, presumably because multiple genetic changes are required for the 
induction of a single full-blown leukemia.  
 The identified RIS were mapped to the mouse genome using the UCSC Genome 
Bioinformatics assembly to identify the chromosomal positions and candidate genes at 
the loci. 19 loci (from a total of 74 leukemic mice) affected more than once by 
retroviral integrations were referred to as common integration sites (CISs) which were 
considered to be near candidate leukemogenic genes (Table 3.2). The relative locations 
of these CIS were compared to the tags from RTCGD and this comparison revealed that 
13 of the CIS correspond to previously known loci. In addition, 6 CIS that were 
detected only by this study, hence designated as Slis (Singapore leukemia integration 
site), and were classified as novel CIS (Table 3.2).  
 The criteria for selection of candidate disease genes are defined as genes near 
CIS which are affected with high frequency in Runx1 Tg/Gata-1.05 mice but affected 
with lower frequency in their respective control mice that may be specifically involved 
in the leukemogenesis of Gata-1-knockdown and Runx1-overexpressing mice. The 
CISs, of special interest, are the genetic changes that occurred preferentially in the 




Table 3.2: Classification of RIS identified in the mouse leukemia model.  
 
CIS indicates common integration site; and RIS, retroviral integration site. 
a The genomic positions of the RISs were determined according to BLAT searching of 
the UCSC Genome Bioinformatics database. 
b Candidate genes in the vicinity of the RIS are shown. 
The bold rows indicate the particularly interesting CIS that are discussed in the text. 
 
In the RIM studies, Ifngr2, Rorc and Notch1, were identified as candidate 
disease genes, two of which are interferon (IFN) signaling-related factors and the other 







3.3 Mutation screening of candidate genes associated with JAK-STAT and 
Notch pathways in AMKL using targeted deep sequencing 
 
Mouse model for AMKL has suggested that JAK-STAT and Notch pathways are the 
key driver mechanism for AMKL leukemogenesis. In addition, subsequent exome 
sequencing on a discovery cohort consisting of 6 paired (onset and complete remission 
times) AMKL patients has indeed identified the mutations in the genes associated with 
JAK-STAT and Notch pathways. To further confirm the genetic mutation in the two 
pathways, targeted deep sequencing for a prevalent cohort consisting of 40 AMKL 
patient samples (onset time only) of which 9 are paired (onset and complete remission 
times) AMKL patients who were registered in the Malaysia-Singapore multicenter 
leukemia study for childhood acute leukemia and 7 AMKL cell lines were performed 
(Appendix I-III). Capturing of genomic DNA (gDNA) fragment was done for coding 
regions of  approximately 600 selected genes including JAK-STAT and Notch pathway 
genes and known leukemia and cancer genes (capture size, 2.9 Mb, SureSelect XT2). 
All captured and barcoded gDNA library were sent for HiSeq2000 sequencing with 
over 300x depth. Subsequent bioinformatics analysis on raw sequence data was 
performed by institutional bioinformatics group. Individual genetic variation was 
subsequently validated in confirmatory Sanger sequencing.  
 Due to time constraints, only mutations in the genes associated with JAK-STAT 
and Notch signaling pathways were confirmed by Sanger sequencing as shown in  
Table 3.3. As germ-line controls were available in a limited number of patients, all the 
identified mutations could not be completely confirmed as somatic mutations. 
Therefore, there is a possibility that part of the identified mutations might be rare single 
nucleotide polymorphisms (SNPs). The variant allele frequency (VAF) is defined as the 
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portion of DNA sequence reads covering the variant position containing the variant 
allele rather than the reference or germ-line allele for single-nucleotide mutations363. In 
general, the VAF directly determines the cellular fraction; for example, a cluster with 
VAF ≥ 0.5 is equivalent to homozygous mutations found in more than 50% of tumor 
cells, or heterozygous mutations in 100% of tumor cells, this would most likely result 
from a non-annotated SNPs or a PCR error occurring upstream of sequencing354. 
Therefore, alterations of VAF ≥ 0.5 were excluded and only mutations that are non -
synonymous are included in the mutated gene list. 
NOTCH2 mutation was the most frequently identified (13 patients, 32.5%), 
followed by GATA-1 (8 patients, 20%), SYNE1 (3 patients, 7.5%), MAML2 (3 patients, 
7.5%), NOTCH4 (2 patients, 5%) and MPL mutations ((2 patients, 5%) as shown in 
Figure 3.2A. Recurrently affected genes are of primary interest in identifying mutations. 
GATA-1 mutations detected in most of the DS-AMKL cases were either small insertions 
or deletions, indicating sufficient sensitivity in the targeted deep sequencing. The 
distribution of alterations in individual frequently mutated genes is displayed in Figure 
3.2C. 
 NOTCH2 was found to be most abundantly expressed in AMKL cell lines 
compared to other Notch family genes, and is reported to be mutated in human 
lymphomas364. In this study, NOTCH2 represents one of the most frequently mutated 
genes in childhood AMKL, as mutations were identified in 3 of 9 DS-AMKL cases 
(33.3%) and in 10 of 31 non-DS-AMKL cases (32.3%) (Figure 3.2B). A representative 
of the mutation found in NOTCH2 is shown in Figure 3.2D. Unlike mutations in T-ALL 
where HD and PEST domains are affected, thereby resulting in Notch activation, the 
mutations found in AMKL are located in the EGF-like repeats region that is required 
for ligand interaction. Thus, these mutations probably ablate Notch signaling. Another 
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Notch family member, NOTCH4, which has been shown to be involved in MK 
differentiation365, was mutated in a single DS-AMKL and non-DS-AMKL cases.  
SYNE1 have been implicated in the regulation of nuclear polarity366, a process 
that operates upstream of NOTCH1 in squamous epithelia and promotes NOTCH1-
dependent epidermal differentiation367. Gene expression profile analysis from another 
study has shown that SYNE1, a spectrin superfamily member, is up-regulated in core-
binding factor–related leukemias368. Heterozygous mutations in SYNE1 were found in 
two DS-AMKL and one non-DS-AMKL cases (Figure 3.2C). 
MAML2 is a non-DNA-binding transcriptional co-activator, associating with the 
CSL-NICD complex required for Notch-induced transcription of Notch target genes. 
Recently, MAML2 was identified as a novel fusion partner of MLL in secondary AML 
and myelodysplastic syndrome (MDS) with inv(11)(q21q23). MAML2 mutations were 
identified in one DS-AMKL cases and two non-DS-AMKL cases (Figure 3.2C). One 
mutation in other MAML family members, MAML1 was observed in the prevalent 
cohort but no mutation was observed in MAML3. 
MPL plays an important role in the development of MKs and platelets as well as 
the self-renewal of hematopoietic stem cells. However, numerous MPL mutations have 
been identified in hematopoietic diseases. The MPL-W515L mutation has been found to 
be as high as 25% in AMKL with myelofibrosis. In this study, MPL mutations were 
only found in a single DS-AMKL and non-DS-AMKL cases (Figure 3.2C).  
A JAK3 somatic mutation was found in one non-DS-AMKL case (Figure 3.2C 
and 3.2E). Another JAK3 mutation was found in the AMKL cell line, MG-S, as 
reported in another AMKL study210. Notably, the domains affected by these mutations 
were different from those previously found in AMKL patients and cell lines. All known 
JAK3 mutations uniformly occurred in the pseudokinase domain or FERM domain208. 
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Despite the relative paucity of somatic mutations, recurrent lesions were 
identified in JAK kinase genes, MPL and GATA1 as being clear mutational targets, 
which have been previously shown to play a role in AMKL209,324. Therefore, this study 
certainly supports such findings and strengthens the importance of such mutations. 
 
 
Table 3.3: Recurrently mutated genes other than GATA-1 in childhood AMKL 













































                            
 
Figure 3.2: Mutations associated with JAK-STAT and Notch pathways in AMKL. 
(A) Frequencies of analyzed gene mutations associated with JAK-STAT and Notch 
pathways. Frequency of each mutated gene is shown.  
(B) Distribution of identified mutations in 52 samples of 13 DS-AMKL cases, 31 
non-DS-AMKL cases and 8 AMKL cell lines. Types of mutations are 
distinguished by color.  
(C) Distribution of JAK3, NOTCH2, SYNE1 and MAML2 alterations. Alterations 
encoded by confirmed somatic mutations are indicated by red arrowheads. The 
JAK3-R657Q mutation was identified in AMKL cell line, MG-S.  
(D) Representative mutation of NOTCH2 confirmed by Sanger sequencing found in 
a DS AMKL patient at onset (top panel) but not at remission time (bottom 
panel) 
(E) Representative mutation of JAK3 confirmed by Sanger sequencing found in a 
non-DS AMKL patient at onset (top panel) but not at remission time (bottom 
panel) 
Abbreviations: +21, trisomy 21; Indel, small insertions or deletions; FERM 
domain, protein 4.1,ezrin, radixin, moesin domain; SH2 domain, Src homology 
2 domain; EGF-like repeats, epidermal growth factor-like repeats; LIN, negative 
regulatory LIN repeats; HD, heterodimerization domain; NRR, negative 
regulatory region; TM, transmembrane domain; RAM, RBPJ associated 
molecule domain; NLS, nuclear localization signal;  ANK, ankyrin repeats; 
TAD, transactivation domain; PEST, proline-glutamate-serine-threonine-rich 
domain; CH domain, calponin-homology domain; KASH domain, 











3.4 Anti-proliferative effects of JAK inhibitor 1 in AMKL cell lines 
 
To investigate the anti-proliferative effect of JAK inhibitor 1 in AMKL cells, a panel of 
human AMKL cell lines was treated with JAK inhibitor 1 at different concentrations, 
and cell viability was determined using the MTS assay. JAK inhibitor 1 induced anti-
proliferative effects in a dose-dependent manner (Figure 3.3A). After 72 hours of 
incubation, the half maximal inhibitory concentration (IC50) values for JAK inhibitor 1 
ranged from 100 to 800 nM (Figure 3.3B); M-07e cells were the most sensitive to JAK 
inhibitor 1 while MEG-01 cells were shown to be resistant to JAK inhibitor 1.  
To further investigate the mechanisms of the anti-proliferative activity of JAK 
inhibitor 1, the inhibitor's effect on apoptosis was determined. Consistent with the MTS 
data in Figure 3.3A, JAK inhibitor 1 induced poly (adenosine diphosphate ribose) 
polymerase cleavage (Figure 3.3C). This was observed after 48 hours of incubation with 
JAK inhibitor 1 at IC50 values used in three representative cell lines, two of which are 
DS-AMKL cell lines (CMK and MG-S) as well as a non-DS AMKL cell line MEG-01. 
 








                    
Figure 3.3: JAK inhibitor 1 inhibits cell proliferation and induced apoptosis in 
AMKL cell lines.  
(A) MTS assay of the eight AMKL cell lines treated with JAK inhibitor 1. Cells 
were incubated with increasing concentrations of JAK inhibitor 1 (0.01 – 8 μM) 
for 72 h. The value for each cell line is the mean ± S.E.M. of two independent 
experiments performed in triplicate.  
(B) IC50 values after AMKL cell lines were incubated with increasing doses of JAK 
inhibitor 1 for 72 h. 
(C) Immunoblotting showing cleavage of poly (adenosine disphophate ribose) 
polymerase (PARP) in CMK, MG-S and MEG-01 cells were treated for 48 h 
with JAK inhibitor 1 at 606 nM, 833 nM and 1 μM, respectively. Control cells 
were treated with dimethyl sulfoxide (DMSO). Blots were stripped and re-




3.5 JAK inhibitor 1 inhibits STAT3 and STAT5 phosphorylation in AMKL 
cells 
 
Activation status of downstream factors, phosphorylated forms of STATs, was 
investigated and STAT1, STAT3 as well as STAT5 were found to be activated in the 
three cell lines in which at least one active phosphorylated member of the JAK family 
was detected. Potent inhibition of STAT3 and STAT5 but not STAT1 phosphorylation 
was observed after 48 hours of incubation with JAK inhibitor 1 at IC50 values in the two 
DS-AMKL cell lines but not in the non-DS AMKL cell line MEG-01 (Figure 3.4). This 
result suggests that STAT3 and STAT5, but not STAT1, may play a dominant role for 




                    
 
Figure 3.4: JAK inhibitor suppresses activation (phosphorylation) of STAT3 and 
STAT5, but not STAT1 in AMKL cells. 
Immunoblotting showing STAT1 Y701, STAT3 Y705 and STAT5 Y694 
phosphorylation in CMK, MG-S and MEG-01 cells were treated for 48 h with JAK 
inhibitor 1 at 606 nM, 833 nM and 1 μM, respectively. Control cells were treated with 




3.6 JAK inhibitor 1 induces suppression of JAK1 and paradoxical 
hyperphosphorylation of JAK3 in AMKL cells 
 
Besides the suppression of STAT phosphorylation by JAK inhibitor 1, its effect on the 
phosphorylation of the JAK family members in AMKL cells was examined. Only the 
tyrosine-phosphorylated forms of JAKs are known to exhibit kinase activity, and 
phosphorylation at two tandem tyrosine residues in the activation loop appears to be 
required for enzymatic activity. Therefore, the effect of JAK inhibitor 1 on the 
phosphorylation status of the JAK family members at the activation loop was 
investigated. Treatment of CMK and MG-S cells, but not MEG-01 cells, with JAK 
inhibitor 1 for 48 hours induced slight but significant inhibition of JAK1 Y1022/1023 
(Figure 3.5). Phosphorylated TYK2 (Y1054/1055) status were not changed in the 
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presence and absence of JAK inhibitor 1 in all AMKL cell lines. In addition, no 
inhibition of JAK2 Y1007/1008 was observed in all AMKL cells incubated with JAK 
inhibitor 1. In contrast, a paradoxical increase in JAK3 Y980/981 phosphorylation was 
observed after 48 hours of incubation of CMK and MG-S cells, but not MEG-01 cells, 
in the presence of JAK inhibitor 1. CMK and MG-S cells were shown to bear activating 
A572V and R657Q mutations in JAK3, respectively, whereas MEG-01 do not carry 
JAK3 mutations.  
   
 
            
 
Figure 3.5: JAK inhibitor induces suppression of JAK1 and paradoxical 
hyperphosphorylation of JAK3 in AMKL cells. 
Immunoblotting showing JAK1 Y1022/1023, JAK2 Y1007/1008, JAK3 Y980/981 and 
TYK2 Y1054/1055 phosphorylation in CMK, MG-S and MEG-01 cells were treated for 
48 h with JAK inhibitor 1 at 606 nM, 833 nM and 1 μM, respectively. Control cells 











3.7 Effect of phenetyl isothiocyanate (PEITC) and γ-secretase inhibitor 
(DAPT) on cell proliferation of AMKL cell lines 
 
Activation of Notch is mediated via the γ-secretase activity of the presenilin-containing 
macromolecular complex. To investigate the anti-proliferative effect of Notch agonist, 
PEITC and γ-secretase inhibitor (GSI), DAPT on AMKL cells, cellular viability was 
measured at 144 hours using standard MTS assay in different AMKL cell lines as GSI, 
which blocks the release of NICD, has been reported to exert growth inhibitory effects 
only after days 5 or 7 in NOTCH1-dependent leukemia cells369. As Notch signaling is 
deregulated in the majority of T-ALL as a result of activating mutations in NOTCH1, 
human T-ALL cell line KOPT-K1, which bears a mutation in the extracellular 
heterodimerization domain of Notch1 that results in ligand-independent S2 
cleavage260,370 was used as a positive control (GSI-sensitive) for DAPT and Jurkat, 
which bears a wild type Notch1 and a mutated FBXW7371 as well as a rare 
juxtamembrane expansion activating NOTCH1 mutations372 was used as a negative 
control (GSI-resistant) for DAPT. After 144  hours of incubation, the growth of most 
AMKL cell lines was suppressed by PEITC in a dose-dependent manner whereas 
PEITC had no significant effect on both T-ALL cell lines (Figure 3.6A). In contrast, 
compared to the GSI-sensitive and GSI-resistant T-ALL cell lines, DAPT had no 
significant effect on the growth of AMKL cell lines. The IC50 was established for 
AMKL cell lines for both PEITC and DAPT (Figure 3.6C). The possible explanation 
for the low IC50 values calculated for both PEITC and DAPT in MG-S after 6 days of 
treatment could be due to cells entered a plateau phase whereby the proliferation is 
greatly reduced or ceased entirely when all growth medium is spent as similar low 
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Figure 3.6: Effect of PEITC and DAPT on cell proliferation of AMKL cells. 
Cells were incubated with increasing concentrations of PEITC (0.1 - 12.8 μM) or DAPT 
(1 – 32 μM) for 144 h. The value for each cell line (A - B) is the mean ± S.E.M. of two 
independent experiments performed in triplicate. 
(A) MTS assay of the eight AMKL and two T-ALL cell lines treated with PEITC. 
(B) MTS assay of the eight AMKL and two T-ALL cell lines treated with DAPT. 
(C) IC50 values of AMKL and T-ALL cell lines treated with PEITC and DAPT for 




3.8 PEITC induces apoptosis via caspase-3/PARP pathway and upregulates 
expression of p21 in AMKL cells 
 
Next, to determine whether the decreased viable cell number of AMKL cells after 
treatment with PEITC was due to induction of apoptosis, three AMKL cell lines were 
treated with PEITC and DAPT for 8 hours followed by annexin V-FITC/ propidium 
iodide staining. Consistent with the MTS data in Figure 3.6A, PEITC induced apoptotic 
cell death but not DAPT (Figure 3.7A). To examine whether PEITC treatment alters the 
expression levels of anti-apoptotic proteins such as Bcl-2 and Bcl-XL, Western blot 
analysis was performed following PEITC treatment. As shown in Figure 3.7B, there 
was no marked difference in the expression of Bcl-2 and Bcl-XL after treatment with 
PEITC for 8 hours. Since activation of caspases is a key hallmark of apoptosis373, the 
effect of PEITC-induced apoptosis on the activation of caspases and cleavage of PARP 
was investigated. Caspase-8 and caspase-9 are known to play critical roles as initiator 
caspases in the extrinsic (death receptor-mediated) and intrinsic (mitochondria-
mediated) apoptotic pathways, respectively. Consistent with induction of apoptosis, 
Western blot analysis revealed that PEITC induced substantial activation of caspase-3 
and caspase-8 in AMKL cells, but to a much lesser extent activation of caspase-9 in 
only CMK and MG-S, thus leading to enhanced PARP cleavage in AMKL cells (Figure 
3.7B). However, no activation of caspase-3 activity (Figure 3.7C) and induction of 
PARP cleavage were observed in AMKL cells treated with DAPT. In addition, cell 
cycle inhibitor, p21 was markedly upregulated by PEITC, which largely mirrored that 






                          
 












                       
            
Figure 3.7: PEITC induces apoptosis via caspase-3/PARP pathway and 
upregulates expression of p21 in AMKL cells. 
(A) Specific apoptosis was determined by flow-cytometric detection of Annexin V-
FITC-positive/PI-negative cells after 8 h incubation in PEITC or DAPT. Control 
cells were treated with dimethyl sulfoxide (DMSO). Bars represent the mean ± 
S.E.M. from three independent experiments.   
(B) Immunoblotting showing Bcl-2, Bcl-XL, cleavage of caspase-3,-8,-9 and poly 
(adenosine disphophate ribose) polymerase (PARP), as well as p21 in CMK, 
MG-S and MEG-01 cells were treated for 8 h with 5 μM PEITC and 30 μM 
DAPT respectively. Control cells were treated with DMSO. Blots were stripped 
and re-probed with anti-GAPDH antibody. 
(C) Caspase-3/7 activities were expressed as the percent change relative to the mean 
luminescence measured for control cells. Bars represent the mean ± S.E.M. from 
three independent experiments. 
(D) Real-time PCR analyses of p21 mRNA levels in AMKL cell lines treated with 
PEITC or DAPT. Control cells were treated with DMSO. Bars represent the 
mean ± S.E.M. of triplicate repeats from two independent experiments. 
For (A) to (C), statistical analysis were performed by two-tailed unpaired Student’s t-




3.9 PEITC induces γ-secretase cleavage of NOTCH1 and enhances 
transcriptional activity of Notch in AMKL cells 
 
To assess the specificity of PEITC on activation of Notch pathway, cleavage of Notch 
was examined. Interestingly, PEITC treatment of the three representative AMKL cell 
lines led to an increase of cleavage of NOTCH1, NICD1, which is the active form of 
the protein (Figure 3.8A). However, DAPT, which known to prevent Notch processing 
and transcriptional signaling, significantly decreased the amount of cleaved NOTCH1 
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in AMKL cells. Also, NOTCH2 protein is constitutively activated in the three AMKL 
cell lines regardless of drug treatment, as shown by its cleavage (NICD2) and these 
AMKL cell lines were shown to contain NOTCH2 mutation located in the EGF-like 
repeats region that is required for ligand interaction, similar to the NOTCH2 mutation 
shown on Figure 3.2D. Further functional studies need to be performed to address 
whether mutations in NOTCH2 ablate Notch signaling. NOTCH1 is activated by a 
series of proteolytic cleavage events, mediated by γ-secretase and other enzymes, 
resulting in the liberation of NICD1. NICD1 then translocates into the nucleus, where it 
binds with RBPJ/CBF-1 and other proteins to form a DNA-binding complex. This 
complex activates transcription of target genes such as hairy enhancer of split 1, HES1. 
Therefore, to determine whether the NOTCH1 induced by PEITC is functionally active, 
dual luciferase reporter assay incorporating the HES1 promoter was used to measure the 
functional activity of NOTCH1. PEITC treatment caused a comparable increase in 
the HES1 promoter activity (Figure 3.8B) and a significant upregulation of the 
endogenous Notch target gene HEY1, as determined by real-time RT-PCR 
(Figure 3.8C). However, a reduction in both endogenous HEY1 mRNA levels and 
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Figure 3.8: PEITC induces γ-secretase cleavage of NOTCH1 and enhances 
transcriptional activity of Notch in AMKL cells. 
(A) Immunoblot showing γ-secretase cleavage of NOTCH1 (Val 1744) and cleavage 
of NOTCH2 in AMKL cells were treated for 8 h with 5 μM PEITC and 30 μM 
DAPT respectively. Control cells were treated with dimethyl sulfoxide 
(DMSO). Blots were stripped and re-probed with anti-GAPDH antibody. 
(B) AMKL cells transfected with HES1-luciferase were either treated with DAPT or 
PEITC, normalized to Renilla determined by dual luciferase reporter assay. Bars 
represent the mean ± S.E.M. from three independent experiments. 
 Statistical significance: *p<0.05, **p<0.001.   
(C) Real-time PCR analyses of HEY1 mRNA levels in AMKL cell lines treated 
with PEITC or DAPT. Control cells were treated with DMSO. Bars represent 
the mean ± S.E.M. of triplicate repeats from two independent experiments. 




3.10 Combination of JAK inhibitor 1 and PEITC trigger synergistic AMKL 
cell death 
 
As combination therapy can maximize effects and minimize side effects of individual 
drugs from a clinical perspective, the synergistic effect of JAK/STAT inhibitor and 
Notch agonist was tested in in vitro experiments. AMKL cell lines such as CMK, MG-S 
and MEG-01 which are relatively more resistant to both PEITC and JAK inhibitor 1 
were selected for the analysis as combination therapy may be able to re-sensitize cells 
to drug-induced apoptosis and produce a greater anti-cancer activity in these cell lines 
compared to the more sensitive cell lines such as M-07e and CMK-86. In this study, 
JAK inhibitor 1 and PEITC were used at concentrations lower than their respective IC50 
for each cell line. CMK, MG-S and MEG-01 cells were treated for 72 hours with doses 
of JAK inhibitor 1, PEITC or the combination and analyzed for viability by MTS assay. 
A more significant decrease in viability of all cell lines tested was noted in response to 
treatment with combined doses of JAK inhibitor 1 and PEITC than with either agent 
alone (p<0.05, n=2; Figure 3.9A-C). Isobologram analysis confirmed that combined 
JAK inhibitor 1 plus PEITC triggered synergistic cell death in AMKL cell lines, albeit 
with differential kinetics.  The drug combination analysis was performed using the 
Chou-Talalay method374. Drug synergy was statistically defined by combination index 
(CI) values less than 1, antagonism by CI >1 and additive effect by CI equal to 1. The 
combination ratio of agents varied for each cell line to achieve a similar degree of cell 
death. These in vitro findings suggest that combination therapy with JAK inhibitor 1 
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Figure 3.9: Combination of JAK inhibitor 1 and PEITC trigger synergistic AMKL 
cell death. 
CMK (A), MG-S (B) and MEG-01 (C) were treated with treated with DMSO, JAK 
inhibitor 1 (blue bar), PEITC (red bar), or combined JAK inhibitor 1 plus PEITC 
(yellow bar) and assessed for viability using MTS assays performed at 72 h. The 
concentration of drugs, either alone or in combination, were as follows: CMK cells: 120 
nM JAK inhibitor 1, 5 μM PEITC or JAK inhibitor 1(120 nM) plus PEITC (5 μM); 
MG-S cells: 400 nM JAK inhibitor 1, 5.5 μM PEITC, or JAK inhibitor 1 (400 nM) plus 
PEITC (5.5 μM); MEG-01 cells: 8 μM JAK inhibitor 1, 6 μM PEITC, or JAK inhibitor 
1 (8 μM) plus PEITC (6 μM). Data presented are means ± S.E.M. (n=2; p <0.05 for all 




CHAPTER 4: DISCUSSION 
 
4.1 Megakaryoblastic leukemia develops in the Runx1 Tg/Gata-1.05 mouse 
model 
 
Earlier studies have demonstrated that Gata1 mutations or trisomy 21 alone are 
insufficient to promote TAM or leukemia in human and mouse, indicating that 
additional cooperating mutations are required for leukemogenesis. Therefore, 
compound mice (Runx1 Tg/Gata-1.05) were subjected to the RIM study to identify 
genetic changes associated with AMKL. 
Morphological analysis of peripheral blood smears from diseased mice 
demonstrated the presence of megakaryoblasts with prominent cytoplasmic blebs. In 
addition, the most widely used markers for examining megakaryoblast such as c-Kit, 
CD61 and CD41 were shown to be positive in most of the compound mice. Therefore, 
flow cytometric analysis confirmed that these compound mice had a disease similar to 
the human AMKL-like leukemia. This result also indicates that Gata-1-knockdown and 
Runx1-overexpressing status drives myeloid features in leukemias despite the strong T-
lymphoid tropism of MoMuLV virus.  
It is important to emphasize that CD41/CD61 were thought to be an integrin 
specific and selective phenotypic markers for the MK/platelet lineage, these markers 
should be used with caution in identifying MK cells as there is increasing evidence that 
CD41 expression is not restricted to cells with potential to differentiate into MK cells, 





Overall, data from my study demonstrate that Gata-1-knockdown and Runx-1 
overexpressing compound mice along with RIM are useful model for the study of the 
molecular mechanisms of multistep AMKL leukemogenesis. 
 
4.2 RIM identifies CIS associated with JAK-STAT and Notch pathways 
 
Identification of RIS in mouse leukemias by inverse PCR revealed several hundreds of 
integration sites in my experimental cohorts of RIM mice. CIS that occur with high 
frequency in compound mice (Runx1 Tg/Gata-1.05), compared to WT controls, would 
provide an insight into the additional genetic alterations required for facilitating the 
progression of compound cells from pre-leukemic state to overt leukemia. Therefore, 
RIM studies on compound mice would be useful to unveil the currently unknown 
mechanistic basis for leukemogenesis in Gata-1-knockdown and Runx1-overexpressing 
mice. 
The RIM result suggested interferon-γ receptor 2 (Ifngr2) as the highest 
potential AMKL gene. IFNGR2 encodes a type I integral membrane protein which 
forms a part of the interferon-γ receptor (IFN-γR). IFN-γ and its downstream signaling 
molecules JAK1/2 and STAT1 are primarily immunity related factors, but they are also 
shown to play a role in the maturation of megakaryocytes145. Of note, IFNGR2 is 
located on human chromosome 21, within the critical region for DS related clinical 
features. It is reported that a small number of DS-AMKL patients carry the mutation of 
JAK2 or JAK3.   
Rorc encodes the TH17-lineage specific transcription factor, RORγt, a member 
of orphan nuclear receptor. TH17 cell is a recently identified IL-17 producing, subclass 
of helper T cells, and has been the subject of much attention, mainly because IL-17 and 
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other cytokines released from TH17 cells are important to the pathogenesis of 
autoimmune diseases and cancer immunity. Notably, TH17 cell differentiation is 
induced by IFN-γ secreted by another helper T cells, TH1 cells.  Therefore, Rorc 
functions as a downstream factor of IFN-γ in TH17 cells. Moreover, RORγt is shown to 
physically interact with Runx1 and induce IL-17 expression together375. IL-17 function 
in myeloid cells is not well documented, but earlier studies suggested that IL-17 also 
stimulates megakaryopiesis376. Although IL-17 production in megakaryoblasts needs 
further investigation, the link of IFN-γ-RORγt-Runx1 is likely to be kept in 
megakaryoblast and its deregulation could lead to AMKL.  
Interestingly, one of the CIS identified was Notch1 gene, where retrovirus 
integrations resulted in gain-of-function mutations that cluster in the carboxy-terminal 
(C-terminal) region of Notch1 containing negative regulatory sequences generating a 
stable expression of its activated product, NICD1. The altered expression in these 
domains is likely to contribute to leukemogenesis by increasing the half-life of 
transcriptionally active NICD1377.  NOTCH1 was also suggested to be a potential 
AMKL gene. Notch family of transmembrane signaling receptors comprises four 
distinct genes. Of these, NOTCH1 is shown to be involved in human solid cancers and 
is frequently mutated in human childhood T-cell leukemia. Recently, Gilliland’s group 
showed that NOTCH1 and NOTCH4 are involved in megakaryocyte differentiation365. 







4.3 Deep sequencing validates genetic alterations associated with JAK-
STAT and Notch pathways in human AMKL samples 
 
A role for the loss of function of Notch in AMKL would predict that Notch signaling 
pathway alterations might be found; indeed, NOTCH2 was found to be frequently 
mutated in AMKL (29.5%) characterized by missense mutations in the EGF-like 
repeats of the Notch ectodomain which is required for ligand interaction378. Mutations 
in other Notch signaling-related genes were also detected by deep sequencing and these 
mutations were validated in my study. Previous studies have shown that point mutations 
of MAML1 were found in three patients with aggressive 5q-AML379 and also mutations 
were found in NOTCH2, MAML1, NCSTN and APH1A in patients with CMML263. 
These Notch inactivating alterations suggest that Notch signaling inhibits AMKL 
growth as well as survival and mutations in a subset of AMKL cells may contribute to 
AMKL leukemogenesis. 
Most of the NGS studies on AMKL mentioned in Introduction were performed 
by exome and transcriptome sequencing. Remarkably, none of the above studies have 
identified Notch signaling pathway genes. Whilst exome sequencing provides a 
platform for genome-wide comprehensive mutation studies; targeted deep sequencing 
offer significant advantages where studies are designed to fulfill specific aims such as 
investigations into the mutational analysis of specific pathways or genes in a clinical 
context. The advantages include increased read depth and decreased off-target noise 
leading to improved sensitivity and specificity for variant detection380 as well as the 
ability to capture and sequence regions not covered by exome capture kits381. My 
understanding through personal communication is that Notch mutations are difficult to 
be detected due to the low capturing efficiency by baits in targeted deep sequencing. In 
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my study, however, I have employed targeted deep sequencing using 20-mer 
biotinylated RNA baits specifically designed to increase the coverage for Notch related 
genes by tiling across targeted genomic regions for Notch, because RIM result has 
suggested that Notch pathway is one of the key driver mechanisms for AMKL 
leukemogenesis. For the same reason, I took the approach to prioritize confirmatory 
Sanger sequencing in Notch signaling pathway genes. In contrast, it is likely that earlier 
NGS studies did not perform confirmatory Sanger sequencing on Notch mutations due 
to the lack of specific interest in Notch signaling pathway.  
Notch alterations in the mouse AMKL model are likely to cause Notch 
activation, whereas alterations in NOTCH2 and NOTCH4 in human AMKL are 
considered to be loss-of-function mutations, based on the domains where mutations are 
mapped. This discrepancy may highlight differential requirement for Notch signaling in 
mouse and human megakaryopoiesis. Observations from previous study has suggested a 
function for Notch/Dll1 signaling in the MK lineage by showing that plating mouse 
Lin−Sca-1+c-Kit+ (LSK) cells on OP9-Dll1 cells resulted in the appearance of mature 
MKs that was not seen in the parental OP9 cells without Notch ligands or in the 
presence of γ-secretase inhibitors365. Conversely, experiments using human CD34+ 
progenitor differentiation assays have shown that Dll4 stimulation inhibited the 
generation of platelets and mature CD41a+ CD42b+ MKs which could be rescued by 








4.4 Retroviral insertional mutagenesis still remains powerful 
 
Leukemogenesis is a multistep molecular process that requires combinations of 
oncogenic mutations, loss-of-function mutations of tumor suppressors, epigenetic 
alterations of gene expression and structural abnormalities of chromosomes331,339. It is 
therefore important to understand how individual genetic alterations cooperate with 
each others. Different high throughput experimental approaches have been developed to 
discover novel cancer genes. The emergence of NGS technologies has revolutionized 
DNA sequencing which has boosted the analysis of cancer genomes at different levels, 
including identification of point mutations, chromosomal aberrations and 
epimutations335.  
Yet there are important limitations to the use of NGS technologies such as the 
presence of a vast background of random mutational noise comprising of single-
nucleotide polymorphisms, germline mutations, PCR errors, or DNA duplications 
which complicates the identification of somatic mutations that actually drive 
leukemogenesis and to distinguish driver mutations from neutral passenger mutations. 
In addition, these approaches require massive amount of tumors to be analyzed to detect 
infrequently mutated driver genes as well as functional interconnection and regulation 
among cancer genes383. RIM on genetically engineered animal models that are 
predisposed to cancer development has been shown to be a powerful strategy to identify 
cooperative genes with pre-existing genetic alteration(s) involved in leukemogenesis 
because the retroviral integrations serve to add specific cooperative genetic changes to 
the pre-existing alterations which can be monitored by observing the development and 
progression of tumors in mice114,384,389. Functional validation for implicated genes, in 
the pathogenesis of the disease is necessary for its clinical relevance. 
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RIM began early in the 20th century by Peyton Rous and others, as a tool for 
cancer gene discovery. However, the immense popularity of NGS has accelerated the 
transition from RIM to NGS leading to the declining use of RIM. In spite of that, NGS 
studies cannot simply substitute functional studies in model organisms as the successful 
identification of Notch signaling pathway in AMKL in my study demonstrates that RIM 
still remains powerful. Consequently, data from functional approaches such as RIM 
serves as a very important complement to other high throughput experimental 
approaches as the RIM studies may be more rational, cost-effective and essential to 
reduce morbidity and mortality from cancer385. 
 
4.5 Potential therapeutic efficacy of JAK inhibition and Notch activation in 
treating AMKL 
 
As JAK/STAT and Notch pathways are suggested to be key pathways in AMKL 
leukemogenesis, JAK inhibitor and Notch agonist were expected to inhibit cell 
proliferation as well as induce apoptosis in AMKL cell lines, and indeed the observed 
results lend further support to my data of the mutation status in AMKL patients. 
 
4.5.1 JAK inhibition suppresses AMKL cell proliferation 
 
In this study, I presented the anti-leukemic activity of a synthetic pan-inhibitor of JAK-
STAT pathway, JAK inhibitor 1 whereby treatment with JAK inhibitor 1 significantly 
reduced AMKL cell proliferation accompanied by an increased in apoptosis as observed 
by the increased cleaved PARP. In the absence of JAK inhibitor 1, three downstream 
STAT proteins were all activated (phosphorylated). Such activation of STAT1 was not 
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changed in the presence of JAK inhibitor 1, whereas activation of STAT3 and STAT5 
were significantly reduced when treated in many AMKL cells, except for MEG-01 cell 
line which is resistant to JAK inhibitor 1. This result suggests that STAT3 and STAT5, 
but not STAT1, may play a dominant role for AMKL cell proliferation. Expression of 
JAK1, JAK2 and TYK2 is ubiquitous; however, expression of JAK3 is restricted to 
hematopoietic cells. JAK inhibitor 1 was shown to induce suppression of JAK1 and 
paradoxical hyperphosphorylation of JAK3 in AMKL cells bearing activating JAK3 
mutations. These data support a crucial role of JAK-STAT in the process of 
proliferation and transformation of AMKL cells which further underlie the significance 
of JAK-STAT in these AMKL cells as a potential therapeutic target and thus provide a 
rationale for attempts to block cytokine activation via the JAK-STAT pathway. 
 
4.5.2 Notch activation attenuates AMKL cell expansion 
 
PEITC is a natural and clinically useful product for chemoprevention of cancer, which 
has recently shown to not only activate Notch pathway but also known to modulate 
other pathways386. Consistent with the detected types of mutation which are considered 
to result in inactivation of Notch pathway, the present study reveals that activation of 
Notch signaling induced by PEITC has been shown to inhibit proliferation of AMKL 
cells. Previous studies have shown that NOTCH1 expression regulates cell death 
through apoptosis387-389. In my study, the results indicate that PEITC efficiently 
promoted the cleavage of caspase-8, an initiator caspase for extrinsic apoptotic 
pathway, resulting in the direct activation of caspase-3 in AMKL cells, which is an 
important effector of apoptotic cell death. Proper functioning of active caspase-3 was 
subsequently demonstrated by the detection of one of its cleaved substrates, PARP. In 
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contrast, there were no obvious changes in the expression of Bcl-2 or Bcl-XL in AMKL 
cells treated with PEITC, which is known to block the release of cytochrome c and 
thereby inhibit activation of caspase-9, an initiator caspase for intrinsic apoptotic 
pathway. Although minimal activation of the intrinsic apoptotic pathway was observed, 
these results suggest that PEITC execute apoptosis mainly by the extrinsic apoptotic 
pathway via caspase activation. In order to confirm the critical involvement of extrinsic 
(caspase-8) or intrinsic (caspase-9) apoptotic pathways in PEITC-induced apoptosis, 
caspase-8 inhibitor (Z-IETD-FMK) and caspase-9 inhibitor (Z-LEHD-FMK) can be 
used to suppress apoptosis in AMKL cells following PEITC treatment. In a parallel 
fashion, Notch signaling in AMKL cells treated with PEITC results in a profound G1 
cell cycle arrest associated with p21waf1/cip1, similar to findings in a previous study on 
Notch signaling in small cell lung cancer cells390. In another study on human prostate 
cancer, PEITC was also shown to promote cell cycle arrest via p53 expression391. 
Moreover, PEITC treatment promotes cleavage of NOTCH1 leading to transcriptional 
activation of Notch target genes, HES1 and HEY1. On the contrary, suppression of 
NOTCH1 activation with gamma-secretase inhibitor which blocks the Notch pathway, 
DAPT, has no effect on the proliferation and apoptosis in AMKL cells. In addition, 
both PEITC and DAPT treatment did not down-regulated the protein expression of 
cleaved NOTCH2. These results suggest that growth inhibitory effect of PEITC is 
independent of NOTCH2 but through the activation of NOTCH1.  In conclusion, the 
present study has established a novel tumor suppressor role for Notch signaling in 
AMKL, and demonstrated that activation of Notch signaling could represent a 





4.5.3 Synergistic cytotoxic effect of JAK inhibitor 1 and PEITC against AMKL 
 
As with other agents, dose-limiting toxicity and the development of resistance limits its 
long-term utility as well as increased mortality in DS-AMKL as did autologous and 
allogeneic transplant392. My study has demonstrated that the combination of low doses 
of JAK inhibitor 1 and PEITC induces apoptosis in AMKL cells that is only achievable 
at much higher doses of either agent alone. Our data demonstrate synergistic 
cytotoxicity of JAK inhibitor 1 and PEITC on AMKL cells, thereby suggesting clinical 
applicability of this combined therapeutic regimen in AMKL.  
JAK-STAT activation and Notch inactivation due to respective genetic mutation 
appear to be the key driver mechanism for AMKL leukemogenesis. Therefore, I 
hypothesize that inhibition of JAK-STAT and activation of Notch are expected to lead 
to cell differentiation and apoptosis (Figure 4.1). 
 
 
Figure 4.1: A proposed model for the role(s) of JAK-STAT and Notch pathways in 
AMKL leukemogenesis and treatment.  
JAK-STAT activation and Notch inactivation due to respective genetic mutation appear 
to be the key driver mechanism for AMKL leukemogenesis. Inhibition of JAK-STAT 






4.6 Future work  
 
To grasp a comprehensive landscape of genetic alterations in AMKL, I am also 
planning to carry out high-resolution single nucleotide polymorphism (SNP) array 
which identifies copy umber variations. In addition, there are several known fusion 
genes such as OTT-MAL and CBFA2T3-GLIS2324 which are common in AMKL. Such 
fusion complementary DNA (cDNA) will also be examined using patient’s cDNAs or 
gDNAs. 
To better define the role of pan-JAK inhibitor compared to more specific JAK-
1,-2 and -3 inhibitors, I intend to use FDA approved clinical agents such as selective 
JAK3 inhibitor, Tofacitinib (CP-690550) or selective JAK1/2 inhibitor, Ruxolitinib 
(INCB018424) on AMKL cell lines. Such comparison with different JAK inhibitors 
will likely provide additional insight into the disease mechanism, as it is conceivable 
that more selective JAK inhibitors might be efficacious with reduced adverse effects, 
which are more highly favorable for translational or clinical application.  
As one of the CIS identified is near the Notch1 gene locus in the mouse AMKL 
model which suggests that Notch1 gene is likely to be activated or upregulated in the 
mouse model, additional experiments to determine the status of Notch1 or Notch2 
activation in mouse AMKL cells and to test both PEITC and DAPT on these cells will 
be carried out.   
In contrast, Notch may be inactivated in human AMKL through mechanisms 
other than mutations, therefore, expression changes in Notch pathway and target genes 
will be further examined. I will next investigate whether the inhibitory effect on cell 
proliferation of PEITC is Notch-specific (independent of NOTCH2 but through the 
activation of NOTCH1), using RNA interference (RNAi) method by introducing small 
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interfering RNA (siRNA)-mediated knockdown of NOTCH1 and NOTCH2 to AMKL 
cells or using plasmid-based approaches for overexpression of NOTCH1 to examine the 
effects on cell proliferation and downstream signaling pathways in AMKL cells. I also 
planned to examine the functional property of the mutated NOTCH2 in human AMKL 
cells by generating stable cell lines expressing the mutant or wildtype variant of 
NOTCH2 using site-directed mutagenesis and to perform functional analysis on 
proliferation and in vitro ligand binding assays.   
To further confirm Notch activation dependent cell killing effect on AMKL 
cells, other Notch agonists, such as anti-Notch antibody which is shown to activate 
Notch pathway, synthetic Notch ligands (Dll4-Fc)393, Notch agonist peptide394 are 
currently listed to be tested. Majority of those molecules have been used to treat cancer 
cells which are caused by loss-of-function mutation in Notch pathway.  
As my results showed that JAK inhibitor and PEITC inhibit cell proliferation 
and induce apoptosis in AMKL cell lines, drug efficacy will be further confirmed using 
in vivo xenograft model employing NOD/SCID/IL2 receptor gamma chain knockout 
(NSG) mice. AMKL cell lines and subsequently, primary AMKL patient cells will be 













Gata-1-knockdown and Runx-1 overexpressing compound mice is a useful mouse 
model for the study of the molecular mechanisms of multistep AMKL leukemogenesis. 
Both RIM and targeted deep sequencing studies revealed that JAK-STAT activation 
and Notch inactivation due to respective genetic mutation appear to be the key driver 
mechanism for AMKL leukemogenesis. Moreover, in vitro drug screening has revealed 
the potential therapeutic efficacy utilizing drugs targeting JAK inhibition and Notch 
activation in treating AMKL. Such hitherto unknown link between JAK-STAT and 
Notch signaling pathways, unveiled in my study, would provide insights into 
fundamental mechanisms of AMKL leukemogenesis, and lead to the improvement of 
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Appendix I: Characteristics of Malaysia-Singapore (MASPORE) AML patients study 2006 
No. DOB Date of Dx Age 













analysis       
(DR Chan) 


















D472 13/08/2007 04/06/2008 0.81 <1 AML-M7 47,XY,+21[9]/46,XY[21
] 
HR CR (after#2), 
BMT 













62.03 10.4 Not 
done 
KL319 13/02/1996 04/10/2005 9.64 1-10 AML-M7 Not done HR CR (after#3), 
Death (Sepsis) 
18/06/2006  18/06/2006   CD117 CD34 CD45 CD61 2.60 41 occ 
KL327 20/04/2005 30/09/2005 0.45 <1 AML-M7 Not done HR CR (after#2), 
Relapsed, 
Death 
09/05/2006 09/07/2006 09/07/2006 09/05/2006 09/05/2006 CD117 CD61 8.30 Occasionally 
Seen 
30 
KL347 17/08/2004 25/11/2005 1.27 1-10 AML-M7 Not done HR CR (after#1), 
Relapse, 
Death 
15/05/2006 01/06/2006 01/06/2006 15/05/2006 15/05/2006 CD117 CD33 CD34 CD56 
CD61 
24.10 23 46 




HR CCR (after#2)      CD33 CD45  CD61 HLADR 6.90 12 90 
KL468 27/06/2005 21/02/2007 1.65 1-10 AML-M7 No metaphase available 
for analysis 
HR CR (after#1), 
Relapse, 
Death 







KL473 11/06/2004 08/03/2007 2.74 1-10 AML-M7 46,XY,t(7;14)(q22;q32),
del(9)(p22),del(13)(q12q
22)[19]/46,XY[1] 
HR No CR 
(after#2), 
Death 
09/03/2007 14/11/2007 14/11/2007  09/03/2007 CD33 CD45 CD61 HLA DR 36.70 41 80 
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No. DOB Date of Dx Age 













analysis         
(DR Chan) 




























05/06/2008   05/06/2008 05/06/2008 CD117 CD13 CD33 CD41a 
CD61 
5.00 3 46 









Down's CCR (after#1)      NA 9.60 25 56 
































Down's CCR (after#3)      FLOW CYTOMETRY OF 
MARROW 
DEMONSTRATES ~22% 
BLASTS WHICH  
EXPRESS CD117+ CD33+ 
CD34+ MPO+ CD36+ 
PARTIAL CD13+(~32%) 
CD7+ TDT- CYTOPLASMIC 
CD3- CD41+. THEREFORE  





12.60 22 31 
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No. DOB Date of Dx Age 













analysis          
(DR Chan) 























monosomy 7 and an 
extra chromosome 21 in 
addition to constitutional 
trisomy 21. This has 
been associated with 
MDS, AML and MPO. ) 
Down's CCR (after#2)      FLOW CYTOMETRY OF 
MARROW 
DEMONSTRATES ~23% 
BLASTS WHICH  
EXPRESS 
CD33+CD117+CD34+ 
PARTIAL CD13+ (~30%) 









TO BE CONSIDERED. 
4.59 13 23 
KL334 05/02/2004 20/10/2005 1.70 1-10 AML-M7-
Down's 
Not done Down's CCR (after#1)      CD19 CD61 7.90   





Down's CCR (after#1)      CD13 CD33 CD34 7.3 22 38 





Down's CCR (after#3)      CD117 CD13 CD33 CD41 
CD61 
26.6 36 35 
 
 





Down's CCR (after#1)      CD117 CD33 CD45 154.00 82 80 





Down's No CR 
(after#2), 
Death 
18/03/2009 04/06/2009 04/06/2009  18/03/2009 CD117 CD11b CD13 CD33 
CD34 CD45 CD61 HLADR 





Appendix II: Characteristics of Malaysia-Singapore AMKL patients (May 2011) 
Lab ID Sex Ethnicity DOB Age 
Dx 
























D210 F Chinese 26/6/1997 5.6 23/1/2003 AML-M7+Down's 
  
None None None Deletion after 70bp None None not done not done None None None 
 
D235 M Malay 21/2/1999 4.8 18/12/2003 AML-M7+Down's 
   
None V617F (G1849T) 
 
None None not done None not done None None 
 
D295 M Chinese 23/01/2003 2.11 04/03/2005 AML-M7 
 
None None None None 
 
None None None None None None None 
 
D298 M Chinese 03/04/2002 3.02 12/04/2005 AML-M7 
   
None None 
 
None None None None None None None 
 
D307 M Chinese 11/06/2004 0.97 01/06/2005 AML-M7+Down's 
 
None None None None 
 
None None None None None None None 
 
D349 M Malay 18/04/2005 1.06 09/05/2006 AML-M7 
  
None None None 
 
None None None None None None None 
 
D352 M Malay 04/10/2004 1.77 12/07/2006 AML M7-Relapse 
      
None None None None None None None 
 
D400 F Vietnamese 26/09/2004 2.59 30/04/2007 AML-M7 
      
None None None None None None None 
 
KKH002 F Chinese 20/06/2004 2.11 01/08/2006 AML-M7-Down's 
      
None None None None None None None 
 
KL187 F Chinese 04/03/1987 16.99 02/03/2004 AML-M7 
 
None None None None Deletion after 70bp None None None None 
Insertion 
3+9bp None None 
 






None None None not done None None None done 
KL319 M Chinese 13/02/1996 9.60 20/09/2005 AML-M7 
 







not done not done not done None None done 
KL327 M Chinese 20/04/2005 0.45 30/09/2005 AML-M7 
  
None None None 
 
None None None None None None None done 
KL334 F Malay 05/02/2004 1.70 20/10/2005 AML-M7+Down's 
   
None None 
 
None None None None None None None 
 
KL347 M Indian 17/08/2005 0.27 25/11/2005 AML-M7 
  
None None None 
 
 
None None None None None None None done 
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Lab ID Sex Ethnicity DOB Age 
Dx 
























KL399 F Chinese 29/12/1998 7.45 12/06/2006 AML-M7 
   
None None 
 
None None None None None None None done 
KL468 F Malay 27/06/2005 1.65 21/02/2007 AML-M7 
      
None None None None None None None 
 
KL473 M Malay 11/06/2004 2.74 08/03/2007 AML-M7 
      
None None None None None None None done 
KL532 F Chinese 13/07/2006 1.21 28/09/2007 AML-M7 
      
None None None None None None None 
 
KL555 F Chinese 24/12/2004 3.07 21/01/2008 AML-M7 
      
None None None None None None None 
 
KKH 32 M Malay 24/05/2005 2.61 04/01/2008 
AML-M7, 
Down's 





Others 03/07/2008 0.71 18/03/2009 AML-M7 





Vietnamese 26/09/2004 2.59 30/04/2007 AML-M7 
           
None None 
 
KL 606 F Chinese 26/09/2006 1.84 31/07/2008 
AML-M7, 
Down's 




                   
done 
R 210 
                   
done 
R 307 









Appendix III: Characteristics of AMKL cell lines used in this study 
Name Source Cell type Remarks Cytogenetics Immunology 
CMK Homo sapiens Acute megakaryoblastic 
leukemia 
Established from the 
peripheral blood of a 10-
month-old boy with Down's 
syndrome and acute 
megakaryocytic leukemia 
(AML M7) at relapse 
Human flat-moded hypotetraploid karyotype with 8% polyploidy 
- 85-90<4n>XY, -X, -Y, -2, -3, +5, -6, -6, -8, +11, -15, -15, +16, -
17, -19, +21, +22, +7-11mar, add(1)(q31), add(1)(p36), 
add(3)(q11), del(3)(p14)x2-3, add(5)(q11), add(5)(q13), 
dup(8)(q11q21), add(8)(q13-21), del(8)(q11), del(9)(p21)x2, 
add(9)(q11)x2, del(10)(q22q24), der(11;17)(q10;q10), 
der(11)dup(11)(p13p15)t(5;11)(q11;p15)x1-2, del(11)(q23), 
add(12)(p13)x2, add(17)(p1?), add(18)(q23)x2-3, add(19)(p13), 
der(20)t(1;20)(q2?5;q1?2)x2, add(22)(q13) - disomic 
rearrangement of 20q1 close to common deleted segment, together 
with additional rearrangements of ch 20 present in markers - 
matches published karyotype 
CD3 -, CD13 +, CD14 -, 
CD15 -, CD19 -, CD33 +, 
CD34 +, CD41 +, CD71 +, 
CD235a + 
CMK-11-5 Homo sapiens Acute megakaryoblastic 
leukemia 
Differentiated subclone of 
CMK, morphologically larger 
than the parent clone CMK 
and contains multinucleated 
giant cells as well as 
possesses more mature 
characteristics than CMK-86 
cells  
 
Not available Expression of CD41a+ and 
CD61+ greater in CMK-11-
5 than in CMK cells, 
positive for platelet 
peroxidase (PPO) activity, 
thrombospondin (TSP) and 
von Willebrand factor 
(vWF)395,396 
CMK-86 Homo sapiens Acute megakaryoblastic 
leukemia 
Differentiated subclone of 
CMK, morphologically larger 
than the parent clone CMK 
and contains multinucleated 
giant cells as well as 
possesses more mature 
characteristics than CMK-86 
cells  
 
Not available CD41+, CD61+, 
Prostaglandin (PG) D 
synthase activity highest in 
CMK-86 compared to 
CMK and CMK-11-5397 
M-07e Homo sapiens Acute megakaryoblastic 
leukemia 
Established from the 
peripheral blood of a 6-
month-old girl with acute 
megakaryoblastic leukemia 
(AML M7) at diagnosis 
Human near-diploid karyotype - 46(45-46)<2n>XX, 





CD3 -, CD13 +, CD14 -, 




Name Source Cell type Remarks Cytogenetics Immunology 




Established from the bone 
marrow of a 55-year-old man 
with chronic myeloid 
leukemia (CML) in 
megakaryocytic blast crisis  
Human hyperdiploid karyotype with 12% polyploidy - 54(53-
56)<2n>XY, +6, +19, +19, +21, +3-4mar, t(1;15)(p13;p13), 
?inv(3)(p25q26), i(4q), add(5)(p15), der(9)t(9;22)(q34;q11)x2, 
add(10)(p14), dup(13)(q13q33-34), add(14)(p11), 
der(22)t(9;22)(q34;q11) - r/dmin x1 present at 57% - sideline with 
i(5)(q10)del(5)(q11q13) instead of add(5) - resembles published 
karyotype;  cells are described to carry t(9;22) leading to BCR-
ABL1 e13-a2 (b2-a2) fusion gene  
CD3 -, CD13 +, CD15 +, 
CD19 -, CD33 + 
MG-S Homo sapiens Acute megakaryoblastic 
leukemia 
Established from a boy with 
Down's syndrome and acute 
megakaryocytic leukemia 
(AML M7) 
Expresses only a truncated mutant of GATA-1 (GATA-1ΔNT) 
which blocks differentiation toward the erythroid lineage100 and 
contains activating  JAK3 mutations (JAK3(Q501H) and 
JAK3(R657Q))210 
Not available 
MOLM16 Homo sapiens Acute myeloid leukemia Established in 1999 from the 
peripheral blood of a 77-year-
old Japanese woman at 
relapse of acute myeloid 
leukemia (AML M0) after 
failed chemotherapy 
Human hypotetraploid karyotype with hypodiploid sideline - 83-
88<4n>XXX, -X, -4, -4, -5, +6, +7, -9, -18, +2mar, 
add(5)(q11)x2, add(6)(q11-13), der6)t(6;9(q16;p13), 
t(6;8)(q15;q24.3), der(8)t(6;8)(q15;q24.3), der(9;18)(p10;q10), 
der(16)del(16)(p13)add(16)(q11), der(16)(del16)(p13)dup(16) 
(q?11q?24)ins(16;?)(q11;??), der(18)t(9;18)(q13;q21), 
der(19)add(19)(p13)add(19)(q13)x2 - resembles published 
karyotype 
CD3 -, CD13 +, CD14 (+), 
CD19 -, CD33 +, CD34 +, 
CD71 +, CD235a + 
UT-7 Homo sapiens Acute myeloid leukemia Established from the bone 
marrow of a 64-year-old man 
with acute myeloid leukemia 
(AML M7) at diagnosis  
Human flat-moded hypotetraploid karyotype - 72-88<4n>XXYY, 
+1, -8, -9, -9, -9, -11, -11, -12, -13, -13, -14, -18, -21, -22, +6mar, 
del(1)(q42)x2, t(2;4)(p16-23;q27-31)x1-2, der(2)t(2;5)(p16-
23;q12-14)x1-2, add(5)(q11), del(5)(q13), der(6;13)(p10;q10), 
i(7q)x1-2, add(8)(q24)x1-3, del(9)(q22), add(12)(p12-13), 
der(13)t(13;13)(p11;q14), add(14)(p11), add(15)(p11), 
add(16)(p1?), add(17)(p11), add(19)(p13)x2, add(19)(q13), 
i(21q)x1-2 - extensive subclonal variation present - resembles 
published karyotype; cells are constitutively cytokine-dependent 
and responsive to various cytokines 
CD3 -, CD4 -, CD13 +, 
CD14 -, CD15 -, CD19 -, 
CD33 +, CD34 -, CD41 
(+), CD42 (+), CD68 +, 
CD235a (+), HLA-DR (+) 
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